Icagen 10Q 2019 Q2 Quarterly report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission File Number000-54748

ICAGEN, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware		20-0982060
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

4222 Emperor Blvd., Suite 350 Research Triangle Park. Durham, NC		27703
Address of Principal Executive Offices		Zip Code

(919) 433-3205

Registrant’s Telephone Number, Including Area Code

Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class	Trading Symbol(s)	Name of each exchange on which registered

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

Number of shares of common stock outstanding as of August 19, 2019 was 6,393,107.

ICAGEN, INC.

NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In particular, statements contained in this Quarterly Report on Form 10-Q, including but not limited to, statements regarding the sufficiency of our cash, our ability to finance our operations and business initiatives and obtain funding for such activities; our future results of operations and financial position, business strategy and plan prospects, or costs and objectives of management for future acquisitions, are forward looking statements. These forward-looking statements relate to our future plans, objectives, expectations and intentions and may be identified by words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “seeks,” “goals,” “estimates,” “predicts,” “potential” and “continue” or similar words. Readers are cautioned that these forward-looking statements are based on our current beliefs, expectations and assumptions and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those identified below, under Part II, Item 1A. “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q, and those identified under Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on April 12, 2019. Therefore, actual results may differ materially and adversely from those expressed, projected or implied in any forward-looking statements. We undertake no obligation to revise or update any forward-looking statements for any reason.

NOTE REGARDING COMPANY REFERENCES

Throughout this Quarterly Report on Form 10-Q, “Icagen,” the “Company,” “we,” “us” and “our” refer to Icagen, Inc.

ICAGEN, INC.

FORM 10-Q

TABLE OF CONTENTS

		Page
	PART I - FINANCIAL INFORMATION
Item l.	Financial Statements	1
	Condensed Consolidated Balance Sheets as of June 30, 2019 (Unaudited) and December 31, 2018	1
	Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2019 and 2018	2
	Unaudited Condensed Consolidated Statements of Stockholders’ Deficit for the three and six months ended June 30, 2019 and 2018.	3
	Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2019 and 2018	5
	Notes to the Unaudited Condensed Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	34
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	45
Item 4.	Controls and Procedures	46

	PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	47
Item 1A.	Risk Factors	47
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	49
Item 3.	Defaults Upon Senior Securities	49
Item 4.	Mine Safety Disclosures	49
Item 5.	Other Information	49
Item 6.	Exhibits	49
SIGNATURES		50

PART I: FINANCIAL INFORMATION

Item 1. Financial Statements

ICAGEN, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30,			December 31,
	2019			2018
	(unaudited)
Assets
Current Assets
Cash	$	929,953		$	4,119,058
Accounts receivable, net		1,332,666			2,051,329
Inventory		152,116			62,792
Prepaid expenses and other current assets		200,822			110,653
Total Current Assets		2,615,557			6,343,832

Non-Current Assets
Intangibles, net		6,936,431			7,048,923
Plant and equipment, net		2,038,503			1,982,845
Right of use assets, net		605,612			-
Deposits		259,599			239,987
Total Non-Current Assets		9,840,145			9,271,755
Total Assets	$	12,455,702		$	15,615,587

Liabilities and Stockholders’ Deficit

Current Liabilities
Accounts payable	$	1,954,108		$	1,721,812
Other payables and accrued expenses		1,092,937			922,457
Deferred revenue		4,506,875			5,090,210
Deferred purchase consideration		2,850,000			2,450,000
Bridge notes payable		290,752			254,641
Finance lease liability		493,052			49,952
Operating lease liability		187,422			-
Accrued interest		275,673			224,475
Dividends payable		391,474			224,855
Total Current Liabilities		12,042,293			10,938,402

Non-Current Liabilities
Deferred purchase consideration, net		5,762,893			6,131,739
Finance lease liability		206,257			18,861
Operating lease liability		419,379			-
Term loan payable, net		13,030,623			12,705,696
Derivative liability		4,466,578			5,178,598
Total Non-Current Liabilities		23,885,730			24,034,894

Total Liabilities		35,928,023			34,973,296

Commitment and contingencies

Stockholders’ Deficit
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 400,000 shares designated as Series A Preferred Stock and unissued, 3,000,000 shares designated as Series B Preferred stock and unissued, 1,142,856 shares designated as Series C Preferred Stock and 5,457,144 undesignated and unissued		-			-
Series C Preferred Stock, $0.001 par value, 1,142,856 shares authorized, 799,989 shares issued and outstanding as of June 30, 2019 and December 31, 2018 (Liquidation preference $4,199,942)		800			800
Common stock, $0.001 par value; 50,000,000 shares authorized, 6,720,107 shares issued and 6,393,107 outstanding as of June 30, 2019 and December 31, 2018.		6,392			6,392
Additional paid-in-capital		28,859,202			27,657,098
Treasury stock, at cost: 327,000 shares of common stock as of June 30, 2019 and December 31, 2018.		(237	)		(237	)
Accumulated deficit		(52,338,479	)		(47,021,762	)
Total Stockholder’s Deficit		(23,472,322	)		(19,357,709	)
Total Liabilities and Stockholders’ Deficit	$	12,455,702		$	15,615,587

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

ICAGEN, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three months ended			Three months ended			Six months ended			Six months ended
	June 30,			June 30,			June 30,			June 30,
	2019			2018			2019			2018

Sales	$	3,905,527		$	4,375,969		$	7,366,038		$	7,457,118

Cost of sales		2,926,359			2,871,930			4,969,346			5,521,244

Gross profit		979,168			1,504,039			2,396,692			1,935,874

Operating expenses:
Selling, general and administrative expenses		3,105,311			2,648,322			5,754,470			5,640,644
Depreciation		366,876			368,274			827,541			825,730
Amortization		56,246			56,246			112,492			112,492
Total Operating expenses		3,528,433			3,072,842			6,694,503			6,578,866

Operating loss		(2,549,267	)		(1,568,803	)		(4,297,811	)		(4,642,992	)

Other income (expense)
Other income		1,599			-			1,599			6,384
Interest expense		(791,066	)		(791,210	)		(1,565,906	)		(1,550,932	)
Derivative liability movement		942,288			(1,140,623	)		712,020			(1,045,537	)
Total other income (expense)		152,821			(1,931,833	)		(852,287	)		(2,590,085	)

Net loss before income tax		(2,396,445	)		(3,500,636	)		(5,150,098	)		(7,233,077	)

Income tax		-			-			-			-

Net loss		(2,396,445	)		(3,500,636	)		(5,150,098	)		(7,233,077	)

Preferred stock dividend		(83,770	)		(59,540	)		(166,619	)		(59,540	)

Net loss available to common stockholders	$	(2,480,215	)	$	(3,560,176	)	$	(5,316,717	)	$	(7,292,617	)

Net Loss Per Share - Basic and Diluted	$	(0.39	)	$	(0.56	)	$	(0.83	)	$	(1.14	)

Weighted Average Number of Shares Outstanding - Basic and Diluted		6,393,107			6,393,107			6,393,107			6,393,107

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

ICAGEN, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2019 AND 2018

									Treasury			Additional					Total
	Preferred Stock				Common Stock				Stock			Paid-in		Accumulated			Stockholders’
	Shares		Amount		Shares		Amount		Amount			Capital		Deficit			Deficit

Balance as of December 31, 2018		799,989	$	800		6,393,107	$	6,392	$	(237	)	$	27,657,098	$	(47,021,762	)	$	(19,357,709	)

Stock option based compensation		-		-		-		-		-			263,938		-			263,938

Net loss		-		-		-		-		-			-		(2,753,653	)		(2,753,653	)

Series C Preferred Stock dividends		-		-		-		-		-			-		(82,849	)		(82,849	)

Balance as of March 31, 2019		799,989		800		6,393,107		6,392		(237	)	$	27,921,036		(49,858,264	)		(21,930,273	)

Stock option based compensation		-		-		-		-		-			938,166		-			938,166

Net loss		-		-		-		-		-			-		(2,396,445	)		(2,396,445	)

Series C Preferred Stock dividends		-		-		-		-		-			-		(83,770	)		(83,770	)

Balance as of June 30, 2019		799,989	$	800		6,393,107	$	6,392	$	(237	)	$	28,859,202	$	(52,338,479	)	$	(23,472,322	)

ICAGEN, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2019 AND 2018 (Continued)

	Preferred Stock Subscription			Preferred Stock				Common Stock				Treasury Stock			Additional Paid-in			Accumulated			Total Stockholders’
	Receipts			Shares		Amount		Shares		Amount		Amount			Capital			Deficit			Deficit

Balance at December 31, 2017	$	-			-	$	-		6,393,107	$	6,392	$	(237	)	$	25,084,252		$	(33,757,671	)	$	(8,667,264	)

Stock option based compensation		-			-		-		-		-		-			153,908			-			153,908

Subscription receipts for Series C Preferred stock		500,000			-		-		-		-		-			-			-			500,000

Net loss		-			-		-		-		-		-			-			(3,372,441	)		(3,500,636	)

Balance at March 31, 2018		500,000			-		-		6,393,107		6,392		(237	)	$	25,238,160			(37,490,112	)		(11,745,797	)

Stock option based compensation		-			-		-		-		-		-			151,712			-			151,712

Series C Preferred stock issued		(500,000	)		599,991		600		-		-		-			2,099,400			-			1,600,000

Fair value of Series C Preferred warrants issued		-			-		-		-		-					(1,386,699	)		-			(1,386,699	)

Net loss		-			-		-		-		-		-			-			(3,500,636	)		(3,500,636	)

Series C Preferred Stock dividends		-			-		-		-		-		-			-			(59,540	)		(59,540	)

Balance as of June 30, 2018	$	-			599,991	$	600		6,393,107	$	6,392	$	(237	)	$	26,102,573		$	(41,050,288	)	$	(14,940,960	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

ICAGEN, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Six months ended			Six months ended
	June 30,			June 30,
	2019			2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(5,150,098	)	$	(7,233,077	)
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation expense		827,541			825,730
Amortization expense		112,492			112,492
Stock based compensation charge		1,202,104			305,620
Amortization of debt discount		355,719			694,010
Derivative liability movements		(712,020	)		1,045,537
Imputed interest on deferred purchase consideration		131,154			149,538
Changes in operating assets and liabilities
Accounts receivable		718,663			(42,925	)
Inventory		(89,324	)		(5,285	)
Prepaid expenses and other current assets		(90,169	)		55,013
Right of use asset		(545,930	)		-
Accounts payable		232,296			1,145,630
Deferred revenues		(583,335	)		(1	)
Right of use liability		547,119			-
Other payables and accrued expenses		221,678			369,290
CASH USED IN OPERATING ACTIVITIES		(2,822,110	)		(2,578,428	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Payment of deferred purchase consideration		(100,000	)		(100,000	)
Purchase of plant and equipment		(883,198	)		(407,727	)
Deposits paid		(19,612	)		-
NET CASH USED IN INVESTING ACTIVITIES		(1,002,810	)		(507,727	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the sale of Series C Convertible Preferred Stock		-			2,100,000
Asset funding advanced		655,133			-
Repayment of Asset financing		(24,637	)		(111,112	)
Refund of capital raising fee		5,319			-
NET CASH PROVIDED BY FINANCING ACTIVITIES		635,815			1,988,888

NET DECREASE IN CASH		(3,189,105	)		(1,097,267	)

CASH AT BEGINNING OF PERIOD		4,119,058			2,763,596

CASH AT END OF PERIOD	$	929,953		$	1,666,329

CASH PAID FOR INTEREST AND TAXES:
Cash paid for income taxes	$	-		$	-
Cash paid for interest	$	1,027,593		$	689,385

NON-CASH INVESTING AND FINANCING ACTIVITIES
Fair value of warrants issued concurrent with Series C Preferred shares	$	-		$	1,386,699

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

GENERAL INFORMATION

Icagen, Inc. (“the Company”, “we”, “us”, “our”) is a Delaware corporation. The principal office is located in Durham, North Carolina. The Company was incorporated in November 2003.

Icagen is a drug discovery company with a focus in Neuroscience and Rare Disease. The Icagen platform is unique as it integrates the Company’s current state of the art drug discovery engine along with an artificial intelligence (AI) computational platform that enables an accelerated path to drug discovery.

The Company’s team is comprised of pharmaceutical and biotechnology leadership with extensive industry knowledge and experience with a successful track record of moving molecules through pre-clinical and clinical development. The Company’s scientific team is derived from two key acquisitions of drug discovery experts in Neuroscience (the “Pfizer Acquisition”) and Rare Disease (the “Sanofi Acquisition”).

The Company’s business model is focused on research collaborations and partnerships with large pharmaceutical and biotechnology companies and foundations who it partners with to support the discovery and development of innovative pharmaceuticals. These revenue-generating partnerships provide current funding for drug discovery services provided while the Company’s co-owned pipeline of drug candidates provides the potential of additional significant long-term upside through milestone and royalty payments in new partnerships. The development and commercialization expense of these assets is being partially funded by the Company’s partners. In addition, the Company also retains a CRO-based fee-for-service revenue stream as a component of the business model.

In May 2018, the Company announced its first such collaboration with the Cystic Fibrosis Foundation to discover therapies to treat cystic fibrosis and in December 2018, it announced its second such collaboration with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, “Roche”) to discover therapies for certain neurological diseases.

The Company currently operates out of two sites, one in Durham, North Carolina (“Icagen NC”) and the other in Tucson, Arizona (the “Tucson Facility”). The teams in North Carolina and Arizona have extensive experience over the last 20 plus years performing drug discovery within Pfizer, Inc. (“Pfizer”) and Sanofi US Inc. (“Sanofi”), respectively, advancing molecules through pre-clinical development with numerous molecules entering clinical development. At Icagen NC, which the Company began to operate in July 2015, it has a leading biology expertise focused on ion channels which are important targets in neuroscience. Icagen NC also houses the XRpro® technology. The XRPro technology is an x-ray fluorescence technology that delivers transporter screening to detect and quantitatively analyze the x-ray signature of elements with an atomic number greater than 12. More specifically, the Company’s capabilities in Icagen NC include a focus on ion channels and transporters, HTS and lead optimization, ion channels, assay development and x-ray fluorescence-based assays.

At the Tucson Facility, which the Company acquired in July 2016, it has leading biology expertise and platform capabilities in Rare Diseases, in silico and computational applications and integrated drug discovery. The Tucson Facility provides capacity in cell models, human biomarkers, and primary human cell and stem cell-based assays. In addition, the Tucson Facility provides compound management services, HTS and Hit identification, in vitro pharmacology, medicinal chemistry, computational chemistry and ADME. The Tucson Facility also features high volume biology with a flexible robotic infrastructure capable of performing high throughput screening in ultra-high 1536 format, enhancing the Company’s depth of expertise running programs in a highly specialized, efficient and cost-effective manner. This enables the Company to offer a broad range of integrated drug discovery services in a growing market. The extensive integrated drug discovery platform and technologies at the Tucson Facility enable the Company to utilize its biology expertise at both Icagen NC and the Tucson Facility to accelerate drug discovery for challenging, but innovative programs and identify quality leads faster.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ACCOUNTING POLICIES AND ESTIMATES

Basis of presentation

The (a) unaudited condensed consolidated balance sheets as of June 30, 2019, which have been derived from the unaudited condensed consolidated financial statements, and as of December 31, 2018, which have been derived from audited consolidated financial statements, and (b) the unaudited condensed consolidated statements of operations , statements of stockholders’ deficit and cash flows of the Company, have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2019 are not necessarily indicative of results that may be expected for the year ending December 31, 2019. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission (“SEC”) on April 12, 2019.

All amounts referred to in the notes to the unaudited condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise.

Consolidation

The unaudited condensed consolidated financial statements include the financial statements of the Company and its subsidiaries in which it has at least a majority voting interest. All significant inter-company accounts and transactions have been eliminated in the unaudited condensed consolidated financial statements. The entities included in these unaudited condensed consolidated financial statements are as follows:

Icagen, Inc. - Parent Company

Icagen Corp - Wholly owned subsidiary

Icagen-T, Inc. - wholly owned subsidiary

Caldera Discovery, Inc. - Wholly owned subsidiary

XRpro Sciences, Inc. - Wholly owned subsidiary

Estimates

The preparation of these unaudited condensed consolidated financial statements in accordance with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The Company continually evaluates its estimates, including those related to bad debts and recovery of long-lived assets. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to the Company’s reported amounts of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the unaudited condensed consolidated financial statements. Significant estimates include the allowance for doubtful accounts, the useful life of plant and equipment and intangible assets, the valuation of certain assets and intangibles acquired from Pfizer, Inc., the assumptions used to calculate fair value of warrants and options granted, in addition to assumptions used to calculate the value of the derivative liability and assumptions used in assessing impairment of long-term assets.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ACCOUNTING POLICIES AND ESTIMATES (continued)

Fair value of financial instruments

The Company adopted the guidance of ASC 820 for fair value measurements which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:

●

Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.

●

Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.

●

Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

The carrying amounts reported in the balance sheets for cash, accounts receivable, loans payable, accounts payable and accrued expenses approximate their fair market value based on the short-term maturity of these instruments. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The Company had recorded a derivative liability for its warrants which contain a cash settlement option upon the occurrence of a fundamental event. The derivative liability measured at fair value using unobservable inputs (Level 3) amounted to $4,466,578 as of June 30, 2019.

ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.

Concentrations of credit risk

The Company’s operations are carried out in the USA. Accordingly, the Company’s business, financial condition and results of operations may be influenced by the political, economic and legal environment in the USA and by the general state of the economy. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, and rates and methods of taxation, among other things.

The Company maintains cash with major financial institutions. The Federal Deposit Insurance Corporation (“FDIC”) provides insurance coverage for deposits of corporations, the current limit of coverage is $250,000. As a result of this coverage the Company cash balances of $500,260 are not covered by the FDIC as of June 30, 2019.

Concentration of major customers

The Company derives its revenues from commercial pharmaceutical and biotechnology companies.

The commercial revenues are currently from several major pharmaceutical companies and smaller biotechnology and pharmaceutical companies.

The Company derived 80.7% of its commercial revenues from four customers during the six months ended June 30, 2019. During the six months ended June 30, 2018 the Company derived 71.0% of its commercial revenue from four major customers. The Company continues its attempts to diversify its customer base.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ACCOUNTING POLICIES AND ESTIMATES (continued)

Total revenues by customer type are as follows:

	Three months ended				Six months ended
	June 30, 2019		June 30, 2018		June 30, 2019		June 30, 2018

Commercial revenue	$	3,715,952	$	4,375,969	$	7,176,463	$	7,457,118
Government grants		189,575		-		189,575		-

	$	3,905,527	$	4,375,969	$	7,366,038	$	7,457,118

Accounts receivable and other receivables

The Company has a policy of reserving for uncollectible accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. As a basis for accurately estimating the likelihood of collection of the Company’s accounts receivable, it considers a number of factors when determining reserves for uncollectable accounts. The Company believes that it uses a reasonably reliable methodology to estimate the collectability of its accounts receivable. The Company reviews its allowances for doubtful accounts on a regular basis. The Company also considers whether the historical economic conditions are comparable to current economic conditions. If the financial condition of its customers or other parties that it has business relations with were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required.

The balance of the receivables provision as at June 30, 2019 and December 31, 2018 was $0. The amount charged to bad debt provision for the three and six months ended June 30, 2019 and 2018 was $0.

Revenue recognition

The Company’s revenue recognition policy is consistent with the requirements of FASB ASC 606, Revenue.

The Company has analyzed its revenue transactions pursuant to ASC 606, Revenue, and it has no material impact as a result of the transition from ASC 605 to ASC 606. The Company’s revenues are recognized when control of the promised services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those services. The Company derives its revenues from the sale of its services, as defined below. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its revenue transactions:

	i.	identify the contract with a customer;
	ii.	identify the performance obligations in the contract;
	iii.	determine the transaction price;
	iv.	allocate the transaction price to performance obligations in the contract; and
	v.	recognize revenue as the performance obligation is satisfied.

Revenue sources consist of commercial revenues, deferred revenue, multi-element collaboration agreements and government grants and contracts.

Commercial revenues

The Company enters into fixed fee commercial development contracts that are associated with the delivery of feasible research on drug candidates and the development of drug candidates. Revenue under these contracts is generally recognized upon delivery or as the development is performed.

Deferred revenue

The Company received and will receive certain revenue in advance of services delivered. This revenue is deferred and only recognized when services have been performed in terms of master services agreements entered into with customers, together with their associated Statements of Work.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ACCOUNTING POLICIES AND ESTIMATES (continued)

Revenue recognition (continued)

Multi-element collaboration agreements

The Company has entered into multiple-element collaboration contracts with customers and has determined that the different revenue generating elements embodied in these contracts are separable and there is sufficient evidence of the fair value of each element to account for these contract elements separately. These contracts elements include:

Upfront payments

The Company receives upfront revenue payments, generally upon closing a collaboration agreement, these revenues are recognized over the expected initial contract timeline as outlined in the collaboration agreement.

ii.

FTE based research payments

The Company receives ongoing revenue for FTE based time spent on the collaboration projects, this revenue is recognized as the services are rendered.

iii.

Development milestones

Revenue contingent upon the achievement of certain agreed upon development milestones is recognized in the period that the development milestone is achieved. The achievement of a development milestone is when the Company’s collaboration partner agrees that the requirements stipulated in the agreement have been met.

iv.

Sales based events

Revenue based on the achievement of certain calendar year net sales is recognized in the period that the sales achieved by the Company’s collaboration partner reach the thresholds as laid out in the agreement.

Royalties earned

Royalties are earned at varying percentages of net product sales for certain periods as defined in the Company’s collaboration agreements, these royalties are recognized as revenue in the period in which a royalty report is received from the Company’s collaboration partners.

Government grants and contracts

The Company generally uses the cost-to-cost measure of progress for all its government contracts, unless it believes another measure will produce a more reliable result. The Company believes that the cost-to-cost measure is the best and most reliable performance indicator of progress on its government contracts as all its contract estimates are based on costs that it expects to incur in performing its government contracts and it has not experienced any significant variations on estimated to actual costs to date. Under the cost-to-cost measure of progress, the extent of progress towards completion is based on the ratio of costs incurred-to-date to the total estimated costs at the completion of the government contract. Revenues, including estimated fees or profits are recorded as costs are incurred.

When estimates of total costs to be incurred on a contract exceed total estimates of revenue to be earned, a provision for the entire loss on the contract is recorded in the period the loss is determined.

Research and development

The remuneration of the Company’s research and development staff, materials used in internal research and development activities, and payments made to third parties in connection with collaborative research and development arrangements, are all expensed as incurred. Where the Company makes a payment to a third party to acquire the right to use a product formula which has received regulatory approval, the payment is accounted for as the acquisition of a license or patent and is capitalized as an intangible asset and amortized over the shorter of the license period or the patent life.

The amount expensed for unrecovered research costs, included in selling, general and administrative expenses during the three and six months ended June 30, 2019 was $506,664 and $1,324,876, and for the three and six months ended June 30, 2018 was $676,583 and $1,535,778, respectively.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

2.	ACCOUNTING POLICIES AND ESTIMATES (continued)

Net income (loss) per share

Basic net income (loss) per share is computed on the basis of the weighted average number of common stock outstanding during the period.

Diluted net income (loss) per share is computed on the basis of the weighted average number of common stock and common stock equivalents outstanding. Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation.

Dilution is computed by applying the treasury stock method for options and warrants. Under this method, “in-the money” options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Dilution is computed by applying the if-converted method for convertible preferred stocks. Under this method, convertible preferred stock is assumed to be converted at the beginning of the period (or at the time of issuance, if later), and preferred dividends (if any) will be added back to determine income applicable to common stock. The shares issuable upon conversion will be added to weighted average number of common stock outstanding. Conversion will be assumed only if it reduces earnings per share (or increases loss per share).

Related parties

Parties are considered to be related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions. All transactions are recorded at fair value of the goods or services exchanged.

Derivative liabilities

The Company has derivative financial instruments as of June 30, 2019 and December 31, 2018.

ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re- measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described.

The accounting treatment of derivative financial instruments requires that the Company record the embedded conversion option and warrants at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date.

The Black-Scholes option valuation model was used to estimate the fair value of the warrants. The model includes subjective input assumptions that can materially affect the fair value estimates. The expected volatility is estimated based on the most recent historical period of time, of other comparative securities, equal to the weighted average life of the options.

Conversion options are recorded as debt discount and are amortized as interest expense over the life of the underlying debt instrument using the effective interest method.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ACCOUNTING POLICIES AND ESTIMATES (continued)

Inventory

Inventory consists of consumables utilized in the Company’s research activities. These consumable inventories are valued at the lower of cost or net realizable value.

Adoption of Accounting Standards

In February 2016, the Financial Accounting Standards Board (“FSAB”) issued Accounting Standards Update (“ASU”), No. 2016-02, Leases (Topic 842) (ASC 842)

The amendments in this update establishes a comprehensive new lease accounting model. The new standard: (a) clarifies the definition of a lease; (b) requires a dual approach to lease classification similar to current lease classifications; and (c) causes lessees to recognize leases on the balance sheet as a lease liability with a corresponding right-of-use asset for leases with a lease-term of more than twelve months. The new standard is effective for fiscal years and interim periods beginning after December 15, 2018, with early adoption permitted. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, including a number of optional practical expedients that entities may elect to apply. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements, an update which provides another transition method, the prospective transition method, which allows entities to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company adopted the new standard on January 1, 2019 using the prospective transition method.

The Company has identified all leases and reviewed the leases to determine the impact of ASC 842 on its consolidated financial statements. The Company has elected to apply the practical expedient to certain classes of leases, whereby the separation of components of leases into lease and non-lease components is not required and all of the practical expedients to all leases, which include not reassessing (1) whether any expired or existing contracts are or contain leases, (2) lease classification for any expired or existing leases, and (3) initial direct costs for any existing leases. The adoption of the new standard resulted in the recording of a right-of-use asset and a lease liability on the consolidated balance sheet on January 1, 2019 of $59,682 and the subsequent amortization of the asset and the lease liability of $59,682. The adoption of ASU 2016-02, as amended, has had no impact on the unaudited condensed consolidated statements of operations or unaudited condensed consolidated statements of cash flows.

Recent accounting pronouncements

The FASB issued several updates during the period, none of these standards are either applicable to the Company or require adoption at a future date and are not expected to have a material impact on the unaudited condensed consolidated financial statements upon adoption.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

GOING CONCERN

As shown in the accompanying unaudited condensed consolidated financial statements, the Company incurred a net loss of $5,150,098 for the six months ended June 30, 2019 and a net loss of $13,039,313 for the year ended December 31, 2018. As of June 30, 2019, and December 31, 2018 the Company had accumulated deficits of $52,338,479 and $47,021,762, respectively. The Company’s working capital position has changed from a deficit of $4,594,570, including deferred revenue of $5,090,210 as of December 31, 2018, to a deficit of $9,426,736, including deferred revenue of $4,506,875 as of June 30, 2019. The deferred revenue includes an upfront payment on a collaboration agreement of $4,647,224. The Company’s working capital is insufficient to meet its short-term cash requirements and fund any future operating losses. These operating losses create an uncertainty about the Company’s ability to continue as a going concern. The Company’s plan, through the acquisition of the assets of Sanofi and Pfizer Research and the continued promotion of its services to existing and potential customers is to generate sufficient revenues to cover its anticipated expenses. The factors mentioned above raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve month period from August 19, 2019, although no assurances can be given as to the Company’s ability to deliver on its revenue plans, or that unforeseen expenses may arise, the management of the Company believes that the revenue to be generated from operations together with additional issuances of equity or other potential financing will provide the necessary funding for the Company to continue as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company is economically dependent upon future capital or financing to fund ongoing operations.

INVENTORY

Inventory represents the value of certain consumables utilized in the Company’s biological screening processes. These consumables are purchased in bulk and expensed as they are utilized.

PREPAID EXPENSES AND OTHER CURRENT ASSETS

	June 30, 2019		December 31, 2018

Prepaid insurance	$	94,826	$	35,723
Prepaid maintenance		99,433		73,992
Prepaid subscriptions		6,563		938
	$	200,822	$	110,653

6.	INTANGIBLE ASSETS

Cell lines and discovery platform

The Company has established a core set of technologies for the discovery of drugs that act upon ion channel targets. All of the assets acquired were developed internally and are based upon its ion channel platform and include the following acquired components:

	●	Extensive cell line and plasmid repositories

	●	Technologies including HTS, electrophysiology, informatics, in vitro and in vivo ADME, animal efficacy and safety models.

The value placed on these individual components is $5,000,500 for cell lines and $1,450,500 for the discovery platform, no initial value has been ascribed to plasmid repositories due to the commodity nature of these plasmids.

The useful life ascribed to the cell lines is indefinite due to the proprietary nature of these internally generated cell lines and will be tested for impairment on a regular basis and the useful life of the acquired discovery platform is expected to be ten years based on the Company’s internal experience on the usefulness of internally generated procedures and protocols used in ion channel drug discovery procedures. The cell lines and discovery platform will be considered for impairment on a regular basis.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

6.	INTANGIBLE ASSETS (continued)

Trade name and trademarks

Pursuant to the terms of the purchase agreement entered into between the Company and Pfizer Research, the name and all rights to the name of Icagen were assigned to the Company. The use of this name, which was the original name of the publicly traded company acquired by Pfizer Research in 2011, has significant value and is a well-known industry name. The value placed on the trade name and trademarks acquired is $637,500. The useful life of the trade name and trademarks is indefinite and will be tested for impairment on a regular basis.

Assembled workforce

In terms of the purchase agreement entered into between the Company and Pfizer Research, the Company agreed to retain the services of the scientific personnel who have extensive knowledge and experience in ion channel research and services. This workforce was originally acquired by Pfizer Research and prior to that had worked for the original Icagen company. The value placed in the assembled workforce acquired is $282,500, the useful life is expected to be ten years based on the Company’s estimate of the useful life of current knowledge and the rate of evolution within the industry.

Patents

The patents the Company holds and pending patent applications consist of the following:

	●	Method for Detecting Binding Events Using Micro X-Ray Fluorescence Spectrometry, which includes an issued U.S. patent that is expected to expire in about 2021;

	●	Flow Method and Apparatus for Screening Chemicals Using Micro X-Ray Fluorescence, which includes issued patents in the U.S., Europe, Japan and Singapore, such patents are expected to expire in 2022;

	●	Method and Apparatus for Detecting Chemical Binding, which includes about 10 issued patents in the U.S., Europe, Japan and Singapore; such patents are expected to expire in 2023;

	●	Drug Development and Manufacturing, which includes an issued U.S. patent that is expected to expire in about 2021;

	●	Advanced Drug Development and Manufacturing, which includes about 20 issued foreign patents, in Europe, Japan, and Hong Kong, expected to expire in about 2026, and a pending application in the U.S. which, if issued, is expected to expire between 2021-2026;

	●	Well Plate/Apparatus for Preparing Samples for Measurement by X-Ray Fluorescence Spectrometry, which includes issued over 15 issued patents in the U.S. Europe, and Japan, which are expected to expire in about 2028, and a pending application in the U.S. which, if issued, is also expected to expire in 2028;

	●	Method and Apparatus for Measuring Protein Post Translational Modification, which includes a patent issued in Japan, which is expected to expire in about 2028 and pending applications in U.S. and Japan, which, if issued, are also expected to expire in about 2028;

	●	Method and Apparatus for Measuring Analyte Transport Across Barriers, which includes 3 issued U.S. patents and issued patents in China and Hong Kong, which are expected to expire in about 2030/2031, and pending applications in U.S., Europe, and China, which, if issued, are also expected to expire in about 2030; and

	●	Method for Analysis Using X-Ray Fluorescence, which includes 4 issued U.S. patents, which is expected to expire in 2031, and a pending U.S. patent application which, if issued, is expected to expire in 2031.

Intangible assets consist of the following:

	June 30, 2019							December 31, 2018
	Cost		Accumulated amortization and impairment			Net book value		Net book value
Cell lines	$	5,153,664	$	(153,164	)	$	5,000,500	$	5,000,500
Discovery platform		1,450,500		(580,200	)		870,300		942,825
Trade names and trademarks		637,500		-			637,500		637,500
Assembled workforce		282,500		(113,000	)		169,500		183,625
Patents		972,000		(713,369	)		258,631		284,473
	$	8,496,164	$	(1,559,733	)	$	6,936,431	$	7,048,923

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

6.	INTANGIBLE ASSETS (continued)

The aggregate amortization expense charged to operations was $56,246 for the three months ended June 30, 2019 and 2018 and $112,492 for the six months ended June 30, 2019 and 2018.

Amortization expense for future periods is summarized as follows:

	Amount

Remainder of 2019	$	112,492
2020		224,984
2021		224,984
2022		224,984
2023 and thereafter		510,987
Total	$	1,298,431

PLANT AND EQUIPMENT

Plant and equipment consists of the following:

	June 30, 2019							December 31, 2018
	Cost		Accumulated depreciation and impairment			Net book value		Net book value

Laboratory equipment	$	3,259,692	$	(1,590,305	)	$	1,669,387	$	1,248,268
Computer software		1,248,433		(939,083	)		309,350		648,578
Computer equipment		112,634		(78,801	)		33,834		44,234
Leasehold improvements		75,511		(49,578	)		25,932		41,765
	$	4,696,270	$	(2,657,767	)	$	2,038,503	$	1,982,845

The aggregate depreciation charge to operations was $366,876 and $368,274 for the three months ended June 30, 2019 and 2018, respectively and $827,541 and $825,730 for the six months ended June 30, 2019 and 2018, respectively. The depreciation policies followed by the Company are described in Note 2.

LEASES

Adoption of ASC Topic 842, “Leases”

On January 1, 2019, the Company adopted Topic 842 using the modified retrospective method applied to leases that were in place as of January 1, 2019. Results for reporting periods beginning after January 1, 2019 are presented under Topic 842, while prior period amounts are not adjusted and continue to be reported in accordance with the Company’s historic accounting under Topic 840. The Company’s portfolio of leases contains both finance and operating leases that relate primarily to real estate agreements and office equipment agreements. Substantially all of the value of the Company’s lease portfolio relates to a real estate sub-lease agreement that was entered into in July 2016.

Practical Expedients and Elections

The Company elected the package of practical expedients permitted under the transition guidance, which allowed the Company to carryforward its historical lease classification, the Company’s assessment on whether a contract is or contains a lease, and its initial direct costs for any leases that exist prior to adoption of the new standard. The Company also elected to combine lease and non-lease components on the office equipment leases and elected the short-term lease recognition exemption for all leases that qualify.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

8.	LEASES (continued)

Discount Rate

To determine the present value of minimum future lease payments for operating leases at January 1, 2019, the Company was required to estimate a rate of interest that it would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment (the “incremental borrowing rate” or “IBR”).

Operating leases

Property leases

The Company determined the appropriate IBR by identifying a reference rate and making adjustments that take into consideration financing options and certain lease-specific circumstances. For the reference rate, the Company used the 5/1 ARM rate and applied a premium factor based on the Company’s present financial position and emerging growth status, the Company determined that 6.14% was an appropriate incremental borrowing rate to apply to its real-estate operating lease.

The Company entered into a new property lease with effect from April 30, 2019 and determined an appropriate IBR by identifying a reference rate and making adjustments that take into consideration financing options and certain lease-specific circumstances. For the reference rate, the Company used the average of the 5/1 ARM rate including an applied a premium factor based on the Company’s present financial position, and the Company’s current borrowing rate provided by third party lenders, the Company determined that 9.78% was an appropriate incremental borrowing rate to apply to its real-estate operating lease.

Office equipment leases

The Company determined the appropriate IBR by calculating the rate implicit in the agreement based on the cost of the equipment, if purchased outright, the expected residual value and the term of the lease installments. The interest rate implicit in these agreements ranged from 23% to 50%. The weighted average discount rates for the office equipment operating leases was 43.1%.

Finance Leases

Laboratory equipment leases

The Company has financed several items of laboratory equipment through vendor financing. The appropriate IBR was calculated by using the rates implicit in the agreements based on the cost of the equipment, the finance lease term and the regular installments due.

The weighted average discount rates for operating and finance leases are as follows:

Operating leases			9.0	%
Finance leases			8.8	%

Right of use assets

Right of use assets are included in the unaudited condensed consolidated Balance Sheet are as follows:

	June 30, 2019

Non-current assets
Right of use assets, operating leases, net of amortization	$	605,612
Right of use assets, finance leases, net of depreciation – included in plant and equipment	$	649,609

The Company acquired laboratory equipment on January 24, 2019 for a purchase consideration of $613,958 and a two year maintenance contract associated with the equipment of $50,341 in terms of a deferred purchase arrangement. The total amount funded by the vendor was $655,133 repayable in twenty-four equal monthly installments of $29,965.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

8.	LEASES (continued)

Total Lease Cost

Individual components of the total lease cost incurred by the Company is as follows:

	Six months ended June 30, 2019

Operating lease expense	$	94,040

Finance lease expense
Depreciation of capitalized finance lease assets		56,309
Interest expense on finance lease liabilities		26,129

Total lease cost	$	176,478

Depreciation of assets held under finance leases is included in depreciation expense. Minimum rental payments under operating leases are recognized on a straight-line basis over the term of the lease.

Maturity of Leases

Finance lease liability

The amount of future minimum lease payments under finance leases are as follows:

	Amount

Remainder of 2019	$	355,999
2020		378,827
2021		29,965
Total undiscounted minimum future lease payments		764,791
Imputed interest		(65,482	)

Total finance lease liability	$	699,309

Disclosed as:
Current portion	$	493,052
Non-current portion		206,257
	$	699,309

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

LEASES (continued)

Maturity of Leases (continued)

Operating lease liability

The amount of future minimum lease payments under operating leases are as follows:

	Amount

Remainder of 2019	$	124,317
2020		242,166
2021		247,264
2022		83,231
Total undiscounted minimum future lease payments		696,978
Imputed interest		(90,177	)

Total operating lease liability	$	606,801

Disclosed as:
Current portion	$	187,422
Non-current portion		419,379
	$	606,801

OTHER PAYABLES AND ACCRUED EXPENSES

	June 30, 2019		December 31, 2018

Bonus accrual	$	681,425	$	508,550
Payroll liabilities		49,861		275,001
Severance cost accrual		-		30,541
Other		361,651		108,365
	$	1,092,937	$	922,457

The Company accrues for bonus accruals in anticipation of making payments based on the achievement of pre-determined goals. Vacation pay unused at the end of the fiscal year is forfeited with no carry over or payments made to employees.

On September 7, 2018, the Company restructured its management team and streamlined operations at its Tucson Facility, thereby reducing head count by a total of nine people. The Company provided severance packages to these employees based on written agreements entered into. The severance costs are amortized over the severance payment period which expired on January 31, 2019.

10.

DEFERRED REVENUE

Deferred revenue consists of the following:

Revenue received in advance from customers

Payments received in advance from customers in terms of the MSA agreements entered into with customers, including the MSA agreement entered into with Sanofi on July 15, 2016 and the up-front payments received from the Company’s collaboration customers. Revenue is recognized on a monthly basis upon agreed rates for the number of employees assigned to certain Sanofi projects and is offset against the payments received from Sanofi in terms of the agreed upon payment schedule, the remaining excess payments received is deferred revenue and is expected to be realized within a 15 month period.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

10.

DEFERRED REVENUE (continued)

Upfront payments from license agreement

The Company entered into a license agreement with F. Hoffmann-La Roche Ltd. (“Roche”), on December 4, 2018, whereby, in terms of the agreement Roche paid the Company an upfront payment of $5,000,000. This upfront payment is recognized as revenue over the initial contact timeline as outlined in the license agreement.

The license agreement entered into with Roche is a multiple-element license agreement that has different revenue generating elements embodied in the agreement. These revenue generating elements include:

Upfront payments

The Company received an upfront payment of $5,000,000 that will be recognized as revenue over the initial contact timeline as outlined in the license agreement.

ii.

FTE based research payments

The Company receives ongoing revenue for FTE based time spent on the collaboration projects, this revenue is recognized as the services are rendered.

iii.

Development milestones

iv.

Sales based events

Royalties earned

The movement in deferred revenue is as follows:

	June 30, 2019			December 31, 2018

Opening balance	$	5,090,210		$	219,828
Cash received in advance		2,914,699			9,249,998
Revenue recognized		(3,498,034	)		(4,379,616	)
	$	4,506,875		$	5,090,210

11.

DEFERRED PURCHASE CONSIDERATION

In terms of the Icagen asset purchase agreement entered into with Pfizer Research (NC) on July 1, 2015, the Company has the following deferred purchase price obligations:

The Company is obligated to pay additional purchase price consideration calculated at the greater of (i) 10% (ten percent) of gross revenues per quarter (exclusive of revenue paid by Sanofi to Icagen-T and revenue generated by Icagen-T) and (ii) $250,000 per quarter up to an aggregate maximum of $10,000,000. These earn out payments are payable quarterly, 60 days after the completion of each calendar quarter. There are no indications that the Company will not meet the maximum earn out payment.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

11.

DEFERRED PURCHASE CONSIDERATION (continued)

The Company amended its agreement with Pfizer Research (NC), Inc. (“the Second Amendment”), whereby the Company, at its option, may defer payment of any amount exceeding $50,000 of the minimum additional purchase price consideration of $250,000 per quarter until December 31, 2018 such that the Company is only required to pay $50,000 per quarter for the quarters ended March 2017 to December 2018. Deferred purchase consideration bears interest at a rate of 12.5% per annum, which interest is payable quarterly. The deferred purchase consideration in terms of this agreement is payable, together with the deferred purchase consideration for the quarter ended March 31, 2019, as one lump sum. The Second Amendment also provides that if there is an Insolvency Event (as such term is defined in the Second Amendment) prior to the time that Pfizer Research (NC), Inc. has received the Maximum Earn Out Payment, then upon such Insolvency Event, the full amount of any Earn Out Shortfall (the difference between the Maximum Earn Out Payment and the amount of all Earn Out Payments paid to date) shall be due and payable without further notice, demand or presentment for payment. The minimum deferred purchase consideration of $50,000 for the quarters ended March 31, 2017 through December 31, 2018 were paid. The Company is currently negotiating an amendment to the agreement.

Deferred purchase consideration is disclosed as follows:

	June 30, 2019			December 31, 2018
Deferred purchase consideration
Opening balance	$	9,754,071		$	9,856,458
Interest due on deferred purchase consideration		99,168			126,576
Repayment		(182,857	)		(228,963	)
Closing balance		9,670,382			9,754,071

Present value discount on future payments
Opening balance		(1,118,261	)		(1,417,336	)
Imputed interest expense		131,154			299,075
Closing balance		(987,107	)		(1,118,261	)

Deferred purchase consideration, net	$	8,683,275		$	8,635,810

Disclosed as follows:
Short-term portion	$	2,850,000		$	2,450,000
Accrued interest		70,382			54,071
Long-term portion		5,762,893			6,131,739
Deferred purchase consideration, net	$	8,683,275		$	8,635,810

12.

BRIDGE NOTES PAYABLE

On August 13, 2018, the Company closed the first tranche of its note and warrant offering of a maximum of one hundred fifty (150) units and entered into a Securities Purchase Agreement (the “Purchase Agreement”) with four accredited investors, which included a trust of which one member of the Company’s Board of Directors is the trustee and two other members of the Board of Directors (the “Purchasers”), pursuant to which the Company issued to the Purchasers an aggregate of fifty (50) units, at a purchase price of $10,000 per unit, each unit consisting of: (i) the Company’s 10% Subordinated Promissory Note in the principal amount of $10,000 due on the earlier of: (x) the date that is twelve (12) months after its issue date or (y) the Company’s receipt of the proceeds of funding from its next collaboration/partnership (the “Note”) and (ii) a five year warrant to purchase 1,500 shares of common stock of the Company for each $10,000 Note investment of the Company at an exercise price of $3.50 per share (the “Warrant”). An aggregate of $500,000 in principal amount of Notes and Warrants to purchase an aggregate of 75,000 shares of common stock were sold at the closing. The gross cash proceeds to the Company from the sale of the fifty (50) units was $500,000.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

12.

BRIDGE NOTES PAYABLE (continued)

The Warrants also contains certain anti-dilution provisions that apply in connection with any stock split, stock dividend, stock combination, recapitalization or similar transaction.

On December 28, 2018, the Company repaid the principal sum of $200,000 of Bridge notes together with interest thereon of $7,616 owed to three Bridge note holders from the proceeds received from the Roche License agreement entered into on December 4, 2018. The remaining Bridge note holder elected not to be repaid in order to preserve the Company’s cash balances.

The movement on bridge notes is as follows:

	June 30, 2019			December 31, 2018
Bridge note liability
Opening balance	$	311,507		$	-
Bridge notes raised		-			500,000
Interest accrued		14,877			19,123
Repayment		-			(207,616	)
Closing balance		326,384			311,507

Discount on bridge notes
Opening balance		(45,359	)		-
Fair value of warrants issued		-			(116,485	)
Amortization of bridge note discount		36,111			71,126
Closing balance		(9,248	)		(45,359	)

Bridge notes, net	$	317,136		$	266,148

Disclosed as follows:
Short-term portion	$	290,752		$	254,641
Accrued interest		26,384			11,507
	$	317,136		$	266,148

13.

TERM LOAN PAYABLE

On August 31, 2018, the Company, and its wholly owned subsidiaries, Icagen Corp., Caldera Discovery, Inc., and XRPro Sciences, Inc., (collectively, the “Subsidiaries”) entered into a Credit Agreement and Guaranty (the “Icagen Credit Agreement”) with the banks and other financial institutions from time to time party thereto, as lenders (collectively, the “Icagen Lenders”) and Perceptive Credit Holdings II, LP, a Delaware limited partnership (“Perceptive”), as administrative agent for the Icagen Lenders (in such capacity, the “Administrative Agent”).

In addition, on August 31, 2018, Icagen-T, Inc., a Delaware corporation, as borrower (“Icagen-T”), the Company, Icagen Corp., Caldera Discovery, and XRPro Sciences entered into a Credit Agreement and Guaranty (the “Icagen-T Credit Agreement” and together with the Icagen Credit Agreement, the “Credit Agreements”) with the banks and other financial institutions from time to time party thereto, as lenders, and Perceptive, as administrative agent for the lenders (in such capacity, the “Icagen-T Administrative Agent”).

The Icagen Credit Agreement provides for a $7,250,000 term loan (the “Icagen Term Loan”), which was drawn in full on August 31, 2018 (the “Closing Date”). The Icagen-T Credit Agreement provides for an $8,000,000 term loan (the “Icagen-T Term Loan” and together with the Icagen Term Loan, the “Term Loans”), which was drawn in full on the Closing Date.

The Company and Icagen-T used the proceeds from the respective Term Loans (i) for general working capital purposes, including, without limitation, business development and licensing purposes, (ii) to repay the convertible debt disclosed in note 14 below; and (iii) to pay fees, costs and expenses incurred in connection with the transactions contemplated by the Credit Agreements.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

13.

TERM LOAN PAYABLE (continued)

Commencing on the last day of each month after August 31, 2020, the Term Loans amortize in an amount equal to 1.0% of the aggregate principal amount of the Term Loans borrowed on the Closing Date.

The Term Loans mature on August 31, 2022 (the “Maturity Date”) unless accelerated pursuant to an event of default, as described below. All amounts outstanding under the Term Loans will be due and payable upon the earlier of the Maturity Date or the acceleration of the loans and commitments upon an event of default.

Amounts borrowed under the Credit Agreements bear interest at a rate per annum equal to the sum of the greater of: (i) the London Interbank Offered Rate (LIBOR) for one month periods and (ii) two and one-quarter percent (2.25%), plus an applicable margin rate of 9.75% per annum (the “Interest Rate”). Furthermore, interest is payable on a monthly basis.

On August 31, 2018, the Company and Icagen-T each paid a non-refundable closing fee of 2% of the Term Loans (or a total of $305,000) pursuant to the terms of the respective Credit Agreements.

Prepayments of the Term Loans (other than certain mandatory prepayments) prior to the Maturity Date are subject to the following prepayment premium based on the aggregate principal amount of the Term Loans as of the date of any such prepayment: (i) on or prior to the first anniversary of the Closing Date, 12% of the aggregate outstanding principal amount of the Term Loan being prepaid, (ii) following the first anniversary or the Closing Date, but on or prior to the second anniversary of the Closing Date, 8% of the aggregate outstanding principal amount of the Term Loan being prepaid, and (iii) at any time after the second anniversary of the Closing Date and on or prior to the third anniversary of the Closing Date, 3% of the aggregate outstanding principal amount of the Term Loan being prepaid.

The repayment of the Term Loans and the Company’s and Icagen-T’s other obligations under the Icagen Credit Agreement or Icagen-T Credit Agreement, as applicable, are guaranteed by each of the Company’s subsidiaries (excluding Icagen-T with respect to the Icagen Credit Agreement).

Pursuant to the terms and conditions of the Security Agreement, dated August 31, 2018, among the Company, the Subsidiaries (excluding Icagen-T with respect to the Icagen Credit Agreement) and Perceptive (the “Icagen Security Agreement”), the Company’s and the Subsidiaries’ obligations under the Icagen Credit Agreement are secured by (i) a first priority lien on all of the existing and after acquired tangible and intangible assets, including intellectual property, of the Company and the Subsidiaries, and (ii) a pledge of 100% of the Company’s equity interests in the Subsidiaries (excluding Icagen-T with respect to the Icagen Credit Agreement). In addition, pursuant to the terms and conditions of the Security Agreement, dated August 31, 2018, among Icagen-T, the Company, the Subsidiaries and Perceptive (the “Icagen-T Security Agreement”), Icagen-T’s, the Company’s and the Subsidiaries’ obligations under the Icagen-T Credit Agreement are secured by (i) a first priority lien on all of the existing and after acquired tangible and intangible assets, including intellectual property, of the Company and the Subsidiaries other than real estate for which they have a second priority lien, and (ii) a pledge of 100% of the Company’s equity interests in the Subsidiaries.

The Credit Agreements contain customary representations, warranties and covenants, including covenants by each of the Company and Icagen-T limiting additional indebtedness, liens, guaranties, mergers and consolidations, substantial asset sales, investments and loans, sale and leasebacks, transactions with affiliates and fundamental changes and acquisitions. The Credit Agreements also contain covenants requiring that the Company and its subsidiaries maintain cash and cash equivalents held in one or more accounts subject to the first priority perfected security interests of the lenders under the Credit Agreements of not less than (a) $1,000,000 following the Closing Date until March 31, 2019, and (b) $1,500,000 at all times thereafter. In addition, the Credit Agreements provide for specified quarterly minimum consolidated net revenue covenants of the Company and its subsidiaries for the trailing twelve month period ended on each such calculation date during the term of the Credit Agreements. The Company is currently in breach of this covenant and has informed the lender.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

13.

TERM LOAN PAYABLE (continued)

The Credit Agreements provide for events of default customary for credit facilities of this type, including but not limited to non-payment of principal and interest, defaults on other debt, misrepresentations, breach of covenants, representations and warranties, change of control, insolvency, bankruptcy and the occurrence of a material adverse effect on the Company and its subsidiaries. After the occurrence of an event of default and for so long as it continues, all outstanding obligations under the Credit Agreements accrue interest at the Interest Rate plus 4% per annum. Upon an event of default relating to insolvency, bankruptcy or receivership, the amounts outstanding under the Credit Agreements will become immediately due and payable. Upon the occurrence and continuation of any other event of default, lenders holding a majority of the outstanding loans and commitments may accelerate payment of all obligations and terminate the Lenders’ commitments under the Credit Agreements.

On May 15, 2017, the Company and Icagen-T entered into a Securities Purchase Agreement with GPB Debt Holdings II, LLC (“GPB”), pursuant to which (i) the Company issued to GPB a three year Senior Secured Convertible Note maturing on May 15, 2020, bearing interest at the rate of 13% per annum in the aggregate principal amount of $2,000,000 (the “Company Note”); and (ii) Icagen-T issued to GPB a three year Senior Secured Convertible Note maturing on May 15, 2020, bearing interest at the rate of 13% per annum, in the aggregate principal amount of $8,000,000 (the Icagen-T Note and together with the Company Note, the “Convertible Notes”). The Company and Icagen-T, respectively, used a portion of the proceeds from their Term Loans to repay all amounts due (principal, accrued and unpaid interest and other charges) as of the Closing Date under the GPB Senior Secured Convertible Notes. On August 31, 2018, the Company and Icagen-T paid $10,308,333 of the proceeds of the Term Loan to repay the outstanding amounts due to GPB, which satisfied all outstanding amounts due to GPB, terminated the loan facility with GPB and terminated all commitments of GPB to extend credit under the notes and the other transaction documents.

In addition, on August 31, 2018, the Company issued to GPB a second amended and restated warrant to purchase 857,143 shares of Common Stock (the “GPB Warrant”), pursuant to which, among other things, GPB was granted piggyback registration rights upon the same terms as the Warrant issued to Perceptive (described below).

In connection with the entry of the Credit Agreements, on August 31, 2018, the Company issued to Perceptive, or its registered assigns, a warrant (the “Warrant”) to purchase 723,550 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The Warrant is exercisable for a period of seven years from the Closing Date and the per-share exercise price of $3.50, subject to certain adjustments as specified in the Warrant (the “Exercise Price”). Upon any exercise of the Warrant, the Exercise Price is payable in cash or, at Perceptive’s option, by withholding a number of shares of Common Stock then issuable upon exercise of the Warrant with an aggregate fair market value equal to the aggregate Exercise Price. The Warrant also contains customary anti-dilution adjustments and price protection.

The Company also granted Perceptive customary demand and piggy-back registration rights with respect to the shares of Common Stock issuable upon exercise of the Warrant. At any time commencing nine months following the closing of a Qualifying PO (as defined in the Warrant) if the Company is not qualified to register securities under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to a registration statement on Form S-3 (or any successor form), then upon the request of the holder(s) of at least 51% of the Warrants and/or shares of Common Stock issuable thereunder (the “Majority Holders”), the Company is obligated, among other things, to (i) file a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) within 90 days following the date on which the request is given for purposes of registering the shares of Common Stock issuable upon exercise of the Warrants, (ii) use its commercially reasonable efforts to have the registration statement declared effective by the SEC as soon as practicable after filing, subject to any cut backs requested by the SEC, and (iii) maintain the registration until all registerable securities may be sold pursuant to Rule 144 under the Securities Act, without restriction as to volume. In addition, at all times after a Qualifying PO, the Company shall use its commercially reasonable efforts to qualify and remain qualified to register securities under the Securities Act pursuant to a registration statement on Form S-3 or any successor form thereto. At any time commencing nine (9) months after such time as the Company shall have qualified for the use of a registration statement on Form S-3, the Majority Holder(s) shall have the right to request registration on Form S-3 or any similar short-form registration. Further, whenever the Company proposes to register any shares of its Common Stock under the Securities Act (with certain exceptions), the Company shall also include in such registration statement, Perceptive’s shares of Common Stock issuable upon exercise of the Warrant, provided that cut backs may apply in certain situations.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

13.

TERM LOAN PAYABLE (continued)

In connection with the entry into of the Credit Agreements, on August 31, 2018, each of the holders of the Company’s 10% Subordinated Promissory Note, entered into an Amended and Restated 10% Subordinated Promissory Notes (the “Subordinated Notes”), to clarify that the subordination provisions of the Subordinated Notes that were applicable to the Convertible Notes were applicable to the lenders under the Credit Agreements and Perceptive.

In connection with the entry into of the Credit Agreements, effective August 31, 2018 (i) each holder of the Company’s Series C Convertible Redeemable Preferred Stock entered into a Subordination Agreement with the lenders under the Credit Agreement and Perceptive prohibiting declaration of and payment of accrued dividends on the Company’s Series C Convertible Redeemable Preferred Stock until payment in full of all amounts owing under the Credit Agreements and (ii) holders of a majority of the Company’s Series C Convertible Redeemable Preferred Stock effected an amendment to the Securities Purchase Agreements executed by the holders of the Company’s Series C Convertible Redeemable Preferred Stock that clarified that references in the Securities Purchase Agreements to the prior lender now included Perceptive and that the registration rights of such holders was subject to approval of each of the prior lender and Perceptive until the shares underlying the warrants to each had been sold or registered on a registration statement that had been declared effective by the Securities and Exchange Commission.

The movement on the term loans is as follows:

	June 30, 2019			December 31, 2018
Term Loan
Opening balance	$	15,408,897		$	-
Term loan issued		-			15,250,000
Interest accrued		938,735			627,330
Repayments		(942,717	)		(468,433	)
Closing balance		15,404,915			15,408,897

Debt discount
Opening balance		(2,544,304	)		-
Debt issuance costs		5,319			(1,006,944	)
Fair value of warrants		-			(1,746,065	)
Amortization of debt discount		319,608			208,705
Closing balance		(2,219,377	)		(2,544,304	)

Term Loan, net	$	13,185,538		$	12,864,593

Disclosed as follows:
Accrued interest	$	154,915		$	158,897
Long-term portion		13,030,623			12,705,696
	$	13,185,538		$	12,864,593

Subsequent to June 30, 2019, the Company paid the accrued interest of $154,915.

14.

CONVERTIBLE LOAN PAYABLE

On May 15, 2017, the Company, and its wholly owned subsidiary, Icagen-T, Inc. (“Icagen-T”), entered into a Securities Purchase Agreement (“Securities Purchase Agreement”), pursuant to which (i) the Company issued to GPB the Company Note which was a three year Senior Secured Convertible Note, which was to mature on May 15, 2020, and bore interest at the rate of 13% per annum, in the aggregate principal amount of $2,000,000 for cash proceeds of $1,920,000 after an original issue discount of $80,000, before deal related expenses; and (ii) Icagen-T issued to the Purchaser the Icagen-T Note which was a three year Senior Secured Convertible Note (“Icagen-T Note”), which was to mature on May 15, 2020, and bore interest at the rate of 13% per annum, in the aggregate principal amount of $8,000,000 for cash proceeds of $7,680,000 after an original issue discount of $320,000, before transaction related expenses. The convertible Notes were each convertible into shares of common stock at a conversion price of $3.50 per share.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

14.

CONVERTIBLE LOAN PAYABLE (continued)

In addition, any time after issuance, so long as no Event of Default had occurred and/or is continuing, each of the Company and Icagen-T, had the right to redeem all or part of each Convertible Note then outstanding, with a minimum prepayment amount of $500,000, at any time upon five (5) business days’ notice to GPB by paying an amount in cash equal to: a range between 101% and 103% of the Conversion Amount being redeemed if paid in full and if an Event of Default had occurred and is continuing GPB had the right to require the Company to redeem the Conversion Amount for an amount of cash equal to a range between 116% and 118% of the Conversion Amount being redeemed. The “Conversion Amount” was defined as the sum of (a) the portion of the principal to be converted, redeemed or otherwise with respect to which this determination is being made, (b) all accrued and unpaid Interest with respect to such portion of such principal, (c) all accrued and unpaid late charges with respect to such portion of such principal and such Interest, if any, and (d) all other amounts due hereunder.

The Convertible Notes contained certain covenants, such as restrictions on the incurrence of indebtedness, the existence of liens, the payment of restricted payments, redemptions, the payment of cash dividends and the transfer of assets. If the Company failed to timely deliver the shares underlying the Notes, it would be subject to certain buy-in provisions.

In addition, pursuant to the Securities Purchase Agreement, the Company and Icagen-T had agreed to provide certain registration rights if Rule 144 under the Securities Act, is unavailable, for the Warrant Shares.

In connection with the Convertible Notes, the Company issued a warrant (the “Purchaser Warrant”) to purchase up to 857,143 shares of common stock at an exercise price of $3.50 per share, subject to applicable adjustments. The Purchaser Warrant expires on May 15, 2022.

In addition, subject to limited exceptions, a holder of the Purchaser Warrant would not have the right to exercise any portion of the Purchaser Warrant if such holder, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of the common stock outstanding immediately after giving effect to its conversion (the “Beneficial Ownership Limitation”). A holder of the Purchaser Warrant could adjust the Beneficial Ownership Limitation upon not less than 61 days’ prior notice to the Company, provided that such Beneficial Ownership Limitation in no event could exceed 9.99%.

The Purchaser Warrant also contained certain anti-dilution provisions that applied in connection with any stock split, stock dividend, stock combination, recapitalization and, issuances of securities at prices below the conversion price or similar transactions.

If, at the time a holder exercises the Purchaser Warrant, there is no effective registration statement available for an issuance of the shares underlying the Purchaser Warrant to the holder, then in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of the Company’s common stock determined according to a formula set forth in the Purchaser Warrant. If the Company fails to timely deliver the shares underlying the Purchaser Warrants, it will be subject to certain buy-in provisions.

The Purchaser Warrant also provides that the Company will not enter into or be party to a Fundamental Transaction (as defined in the Purchaser Warrant) unless (i) the Successor Entity (as defined in the Purchaser Warrant) assumes in writing all of the obligations of the Company under the Purchaser Warrant and the other Transaction Documents (as defined in the Securities Purchase Agreement) pursuant to written agreements in form and substance satisfactory to the Purchaser, including agreements to deliver to the Purchaser in exchange for the Purchaser Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to the Purchaser Warrant; (ii) the Company or the Successor Entity (as the case may be) agrees at the election of the Company or the Successor Entity (as the case may be) to purchase the Purchaser Warrant from the Purchaser by paying to the Purchaser cash in an amount equal to the Black Scholes Value (as defined in the Purchaser Warrant); or (iii) the Purchaser, at its election, requires the Company or the Successor Entity (as the case may be) to purchase the Purchaser Warrant from the Purchaser by paying to the Purchaser cash in an amount equal to the Black Scholes Value.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

14.

CONVERTIBLE LOAN PAYABLE (continued)

The Company Note was secured by a security interest in all of the existing and future assets of the Company and the domestic subsidiaries, other than Icagen-T, including a pledge of all of the capital stock of each of the Domestic Subsidiaries, other than Icagen-T, subject to existing security interests, for the benefit of GPB, to secure the Company obligations under the Company Note, as evidenced by (i) a security and pledge agreement, and (ii) a guaranty executed by each Domestic Subsidiary, other than Icagen-T, pursuant to which the domestic subsidiaries, other than Icagen-T, guaranteed all obligations of the Company under the Transaction Documents.

The Icagen-T Note was secured by a security interest in all of the existing and future assets of the Company, Icagen-T and the other Domestic Subsidiaries, including a pledge of all of the capital stock of each of the Domestic Subsidiaries, other than Icagen-T, subject to existing security interests, for the benefit of GPB, to secure Icagen-T’s obligations under the Icagen-T Note, as evidenced by (i) a security and pledge agreement, and (ii) a guaranty executed by the Company and each Domestic Subsidiary, other than Icagen-T, pursuant to which the Company and the Domestic Subsidiaries, other than Icagen-T, guaranteed all of the obligations of Icagen-T under the Transaction Documents.

In addition, the Company and Icagen-T entered into a Subordinated Deed of Trust, Assignment of Rents, Fixture Filing and Security Agreement with the trustee named therein and GPB as beneficiary, securing all of Icagen-T’s obligations to GPB by a senior priority security interest in the Property/Facilities, which was subordinated only to a Deed of Trust entered into with Sanofi.

Upon an Event of Default, GPB could, among other things, collect or take possession of the Company collateral or Icagen-T collateral, as the case may be, proceed with the foreclosure of the security interest in the collateral or sell, lease or dispose of the collateral. Each of the Subsidiaries had also guaranteed all of the Company’s obligations under the Company Note pursuant to the terms of the Company Guaranty and the Icagen-T Guaranty.

On August 31, 2018 the Company raised an aggregate of $15,250,000 in principal amount of term loans from Perceptive (note 13 above) and exercised its right to redeem the convertible notes in the principal amount of $10,000,000 that had been issued in May 2017 by the payment of the aggregate principal outstanding amount of $10,000,000, plus accrued interest thereon of $108,333 and an early redemption cash payment of $200,000. The Company recorded a net gain on extinguishment of $495,783 of convertible debt, related accrued interest, derivative liability, unamortized discount and early redemption cash payment during the year ended December 31, 2018.

The movement on convertible debt is as follows:

	December 31, 2018
Convertible debt
Opening balance	$	10,108,333
Interest accrued		866,667
Early settlement penalty		200,000
Repayments		(11,175,000	)
Closing balance		-

Debt discount
Opening balance		(4,138,206	)
Amortization of debt discount		950,163
Release of debt discount on extinguishment of convertible debt		3,188,043
Closing balance		-

Convertible debt, net	$	-

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

15.

DERIVATIVE LIABILITY

The Purchaser Warrants issued to the note holders, disclosed in note 14 above, had variable priced conversion rights which could adjust whenever new securities were issued at prices lower than the current exercise price of the Purchaser Warrants issued to note holders as well as a possible cash settlement option upon the happening of a fundamental event. This gave rise to a derivative financial liability, which was initially valued upon the issue of the Purchaser Warrants using a Black-Scholes valuation model. The Purchaser Warrants issued in connection with the Convertible Notes were valued at $1,448,629.

Between April 2018 and August 2018 the Company closed four tranches of the Series C Preferred units, discussed in note 16 below. Each Preferred Series C unit includes warrants exercisable over 28,571 shares of common stock at an initial exercise price of $3.50 per share subject to anti-dilution pricing adjustments and a cash settlement option upon the happening of a fundamental event. This gave rise to a derivative financial liability which was initially valued using a Black Scholes valuation model at $1,858,663.

On August 31, 2018, in connection with the entry into the Credit Agreements described in note 13 above, the Company issued to Perceptive, or its registered assigns, a warrant to purchase 723,550 shares of the Company’s common stock, par value $0.001 per share. The warrant is exercisable for a period of seven years from August 31, 2018 and the per-share exercise price is $3.50, subject to certain adjustments as specified in the warrant (the “Exercise Price”). Upon any exercise of the Warrant, the Exercise Price is payable in cash or, at the holder’s option, by withholding a number of shares of Common Stock then issuable upon exercise of the Warrant with an aggregate fair market value equal to the aggregate Exercise Price. The Warrant also contains customary anti-dilution adjustments and price protection. The pricing adjustments stipulated in the warrant give rise to a derivative liability which was initially valued using a Black Scholes valuation model at $1,746,065.

The following assumptions were used in the Black-Scholes valuation model:

	Six months ended June 30, 2019

Calculated stock price	$	3.50
Risk free interest rate		1.7 to 2.3	%
Valuation period		2.9 to 6.2 years
expected volatility of underlying stock		60.1% to 82.2	%
Expected dividend rate		0	%

The movement in derivative liability is as follows:

	June 30, 2019			December 31, 2018

Opening balance	$	5,178,598		$	4,168,964
Derivative liability on warrants issued to term loan note holders and series C preferred stockholders		-			3,604,728
Extinguishment of derivative liability on convertible debt		-			(3,890,826	)
Mark-to-market adjustment		(712,020	)		1,295,732
Closing balance	$	4,466,578		$	5,178,598

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

16.

PREFERRED STOCK

Preferred Stock consists of 10,000,000 authorized preferred shares of $0.001 par value each, of which 400,000 are designated as Series A 8% convertible redeemable preferred shares of $0.001 each, 3,000,000 are designated as Series B convertible preferred shares of $0.001 each, and 1,142,856 are designated as Series C convertible redeemable preferred shares of $0.001 each with the remaining 5,457,144 preferred shares remaining undesignated.

Series A 8% convertible, redeemable preferred stock (“Series A Stock”)

Series A Stock consists of 400,000 designated shares of $0.001 par value each, 0 shares issued and outstanding as of June 30, 2019 and December 31, 2018.

Series B convertible preferred stock (“Series B Stock”)

Series B Stock consists of 3,000,000 designated shares of $0.001 each, 0 shares outstanding as of June 30, 2019 and December 31, 2018.

Series C convertible, redeemable preferred stock (“Series C Stock”)

Series C Stock consists of 1,142,856 authorized shares of $0.001 each, of which 799,989 shares are issued and outstanding as of June 30, 2019 and December 31, 2018.

On April 3, 2018, the Company filed the Certificate of Designation with the Secretary of State of the State of Delaware establishing the Series C Stock which entitles each holder of Series C Stock to a cumulative dividend at the rate of 12.0% per annum, payable quarterly in arrears.

The Company has offered on a best efforts basis up to a maximum of forty (40) units and a minimum of ten (10) units, at a purchase price of $100,000 per unit (“Series C Unit”), each unit consisting of 28,571 shares of Series C Stock, par value $0.001 per share and a seven year Warrant to acquire 28,571 shares of the Company’s common stock, par value, $0.001 per share, at an exercise price of $3.50 per share.

The Series C Stock ranks senior to the shares of the Company’s common stock, and any other class or series of stock issued by the Company with respect to dividend rights, redemption rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of its affairs. Holders of Series C Stock are entitled to a cumulative dividend at the rate of 12.0% per annum, as set forth in the Certificate of Designation of Series C Stock. The Series C Stock is convertible at the option of the holders at any time into such number of shares of common stock as shall be equal to the gross proceeds received on the issuance of the Series C Stock plus any accrued and unpaid dividends on such share of Series C Stock (the “Accreted Value”) divided by the conversion price, which initially is $3.50 per share, subject to certain customary anti-dilution adjustments. In addition, the Series C Stock automatically converts into shares of the Company’s common stock based upon the then effective conversion price upon the (i) closing of a sale of shares of common stock to the public in a Qualifying Public Offering (as defined below) or a reverse merger into a publicly reporting company that has its common stock listed or quoted and traded on a Trading Market (as such term is defined in the Certificate of Designation) or (ii) the date and time, or the occurrence of an event, specified by vote or written consent of the holders of at least seventy-five percent (75%) of the outstanding shares of Series C Stock (the “Requisite Holders”) (the time of such closing or the date and time specified of the event specified in such vote or written consent is referred to herein as the “Mandatory Conversion Date”). A “Qualifying Public Offering” is defined as the first firm commitment underwritten public offering by the Company on or following the initial issuance date of the Series C Stock in which shares of common stock are sold for its account solely for cash to the public resulting in proceeds to it and/or its subsidiary, Icagen-T, Inc. of no less than $8,000,000 (after deduction only of underwriter discounts and commissions) and where the shares of common stock registered under the Securities Act of 1933, as amended, and sold in such public offering are simultaneously listed and commence trading on a Trading Market (as such term is defined in the Certificate of Designation)

In the event of any liquidation, dissolution or winding-up of the Company, holders of the Series C Stock shall be entitled to a preference on liquidation equal to $5.25 per share of Series C Stock plus all accrued and unpaid dividends.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

16.

PREFERRED STOCK (continued)

Series C convertible, redeemable preferred stock (“Series C Stock”) (continued)

Each holder of Series C Stock has the right to cast the number of votes equal to three times the number of shares into which the Series C Stock is convertible and the Series C holders as a group, has the right to elect one director on the Company’s Board of Directors. The Company cannot take the following actions without the approval of the Requisite Holders and the consent of its Board of Directors, including the Series C Stock director: (i) liquidate, dissolve or wind up its business, (ii) amend its Certificate of Incorporation or Bylaws, (iii) create any new class of stock unless it ranks junior to the Series C Stock with respect to dividends and liquidation, (iv) amend or alter any class of stock pari passu with the Series C Stock to make it senior with respect to dividends and liquidation, (v) purchase or redeem any other shares of its stock, or (vi) increase the size of its Board of Directors.

Upon the occurrence of a Cash Liquidity Event, the holders of the Series C Stock can require the Company to redeem their shares of Series C Stock for a price per share equal to $5.25 subject to adjustments. In addition, the Company has the right to redeem the shares at any time for a price per share equal to $5.25 subject to adjustments. A “Cash Liquidity Event” is defined as the closing of any sale, lease or licensing transaction relating to a single asset or multiple assets other than in the ordinary course of the Company’s business, including, but not limited to a sale of a building, sale of biological assets or other upfront payments, resulting in aggregate gross proceeds received by the Company at closing or closings in a transaction or transactions during any twelve (12) month period in excess of $40,000,000.

During the three months ended June 30, 2019 and 2018, the Company had accrued dividends of $83,770 and $59,540, respectively and for the six months ended June 30, 2019 and 2018, the Company has accrued dividends of $166,619 and $59,540, respectively on the Series C Stock.

17.

COMMON STOCK

Common stock consists of 50,000,000 authorized shares of $0.001 each, 6,720,107 shares issued and 6,393,107 shares outstanding as of June 30, 2019 and December 31, 2018.

18.

WARRANTS

Between April 2018 and August 2018, the Company closed on four tranches of 28 Series C Units for gross proceeds of $2,800,000, resulting in warrants exercisable over 799,989 shares of common stock at an initial exercise price of $3.50 per share. These warrants were initially valued at $1,858,663 using a Black Scholes pricing model.

In terms of the Company’s bridge note offering on August 13, 2018, the Company closed the first tranche of its note and warrant offering of an aggregate of fifty (50) units, at a purchase price of $10,000 per unit, each unit including a five year warrant to purchase 1,500 shares of common stock of the Company at an exercise price of $3.50 per share, resulting in warrants exercisable over 75,000 shares of common stock being issued. The Warrants also contains certain anti-dilution provisions that apply in connection with any stock split, stock dividend, stock combination, recapitalization or similar transaction. These warrants were valued at $116,485 using a Black Scholes pricing model.

In connection with the entry of the Credit Agreements, on August 31, 2018, the Company issued a warrant to purchase 723,550 shares of the Company’s common stock. The warrant is exercisable for a period of seven years at an exercise price of $3.50 per share, subject to certain adjustments as specified in the Warrant. Upon any exercise of the Warrant, the Exercise Price is payable in cash or, at the warrant holders option, by withholding a number of shares of Common Stock then issuable upon exercise of the Warrant with an aggregate fair market value equal to the aggregate Exercise Price. The Warrant also contains customary anti-dilution adjustments and price protection. These warrants were valued at $1,746,065 using a Black Scholes pricing model.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

18.

WARRANTS (continued)

A summary of the Company’s warrant activity during the period January 1, 2018 to June 30, 2019 is as follows:

	Number of shares			Exercise price per share		Weighted average exercise price

Outstanding January 1, 2018		3,179,784			$ 3.50 to $4.20	$	3.50
Granted		1,598,539			3.50		3.50
Forfeited/cancelled		(75,000	)		4.20		4.20
Exercised		-			-		-
Outstanding December 31, 2018		4,703,323			3.50 to 3.85		3.51
Granted		-			-		-
Forfeited/cancelled		-			-		-
Exercised		-			-		-
Outstanding June 30, 2019		4,703,323			$ 3.50 to $3.85	$	3.51

The following table summarizes warrants outstanding and exercisable as of June 30, 2019:

		Warrants outstanding						Warrants exercisable
Exercise price		Number of shares		Weighted average remaining years		Weighted average exercise price		Number of shares		Weighted average exercise price

$	3.50		4,559,922		3.09				4,559,922
$	3.85		143,401		1.00				143,401
			4,703,323		3.02	$	3.51		4,703,323	$	3.51

The Warrants outstanding at June 30, 2019 have an intrinsic value of $0.

19.

STOCK OPTIONS

In October 2005, the board of directors adopted the Caldera Pharmaceuticals, Inc. 2005 Stock Option Plan (the “Plan”), which permitted awards of incentive and nonqualified stock options and other forms of incentive compensation to employees and non- employees such as directors and consultants. The Board had set aside 1,500,000 shares of common stock for issuance upon exercise of grants made under the Plan. Options granted under the Plan vest either immediately or over a period of up to two years, and expire 1 year to 10 years from the grant date. In terms of the Plan agreement, the plan expired during October 2015, ten years after its adoption, therefore there are no further options available under this plan for future grants.

On December 9, 2015, the board of directors approved the 2015 Stock Incentive Plan which was approved by the Company’s stockholders exercising approximately 50.2% of the Company’s voting power. The plan became effective on March 26, 2016, 20 days following the mailing of an information statement to the Company’s stockholders.

The 2015 Stock Incentive Plan (“the 2015 Plan”) provides the directors, officers, employees and consultants of the Company with appropriate incentives and rewards to encourage them to enter into and continue in the employ or service of the Company, to acquire a proprietary interest in the long-term success of the Company and to reward the performance of individuals in fulfilling long-term corporate objectives. The Board initially set aside 800,000 shares of common stock for issuance upon exercise of grants made under the Plan and increased the number of shares available under the plan by a further 800,000 shares of common stock during 2016 to a total of 1,600,000 shares of common stock. Options granted under the Plan vest either immediately or over a period of time, determined at the grant date and will expire over a period of time, determined at the grant date.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

19.

STOCK OPTIONS (continued)

On December 4, 2018, the board of directors approved the 2018 Stock Incentive Plan which was approved by the Company’s stockholders exercising approximately 51.5% of the voting power. The plan became effective on December 31, 2018, 20 days after the mailing of an information statement to the Company’s stockholders.

The 2018 Stock Incentive Plan (“the 2018 Plan”) provides the directors, officers, employees and consultants of the Company with appropriate incentives and rewards to encourage them to enter into and continue in the employ or service of the Company, to acquire a proprietary interest in the long-term success of the Company and to reward the performance of individuals in fulfilling long-term corporate objectives. The board of directors set aside 2,000,000 shares of common stock for issuance upon exercise of grants made under the 2018 Plan. Options granted under the 2018 Plan vest either immediately or over a period of time, determined at the grant date and will expire over a period of time, determined at the grant date.

On April 30, 2019, the Company granted ten-year options exercisable for 628,883 shares of common stock, at an exercise price of $3.50 per share, under the 2018 Plan. Included in the grant are ten-year options exercisable for 154,616 and 75,267 shares of common stock, at an exercise price of $3.50 per share, with immediate vesting, granted to the Company’s Chief Executive Officer and the Company’s Chief Scientific Officer, respectively. The remaining options exercisable for 399,000 shares of common stock were issued to employees of the Company vesting over a three year period.

Options exercisable for 22,986 and 113,946 shares of common stock for the six months ended June 30, 2019 and the year ended December 31, 2018 expired and were cancelled.

A summary of all of the Company’s option activity during the period January 1, 2018 to June 30, 2019 is as follows:

	Number of shares			Exercise price per share		Weighted average exercise price

Outstanding January 1, 2018		1,419,959			$ 0.40 to $11.42	$	3.59
Granted		1,005,000			3.50		3.50
Forfeited/cancelled		(113,946	)		3.50		(3.50	)
Exercised		-			-		-
Outstanding December 31, 2018		2,311,013			0.40 to 11.42		3.55
Granted		628,883			3.50		3.50
Forfeited/cancelled		(22,986	)		3.50 to 5.00		4.15
Exercised		-			-		-
Outstanding June 30, 2019		2,916,910			$ 0.40 to $11.42	$	3.54

The following tables summarize information about stock options outstanding as of June 30, 2019:

		Options outstanding						Options exercisable
Exercise price		Number of shares		Weighted average remaining years		Weighted average exercise price		Number of shares		Weighted average exercise price

$	0.40		15,000		2.84				15,000
$	3.00		312,500		3.71				312,500
$	3.50		2,446,119		8.59				1,361,230
$	4.00		8,791		0.53				8,791
$	5.00		118,500		1.63				118,500
$	11.42		16,000		2.18				16,000
			2,916,910		7.69	$	3.54		1,832,021	$	3.56

The weighted-average grant-date fair values of options granted during the six months ended June 30, 2019 was $1,661,524 ($2.64 per share) and for the year ended December 31, 2018 was $2,801,944 ($2.79 per share). As of June 30, 2019, there were unvested options to purchase 1,084,889 shares of common stock. Total expected unrecognized compensation cost related to such unvested options is $2,725,827 which is expected to be recognized over a period of 34 months.

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

19.

STOCK OPTIONS (continued)

Stock option-based compensation expense totaled $938,166 and $151,712 for the three months ended June 30, 2019 and 2018, respectively, and $1,202,104 and $305,620 for the six months ended June 30, 2019 and 2018, respectively.

Stock options outstanding as of June 30, 2019 as disclosed in the above table, have an intrinsic value of $202,750.

20.

INTEREST EXPENSE

Interest expense consists of the following:

	Three months ended June 30, 2019			Three months ended June 30, 2018			Six months ended June 30, 2019			Six months ended June 30, 2018

Imputed interest	$	(65,577	)	$	(74,769	)	$	(131,154	)	$	(149,538	)
Debt discount		(179,450	)		(358,625	)		(355,719	)		(694,010	)
Interest expense		(545,797	)		(357,816	)		(1,078,791	)		(706,845	)
Other		(242	)		-			(242	)		(539	)
	$	(791,066	)	$	(791,210	)	$	(1,565,906	)	$	(1,550,932	)

21.

NET LOSS PER COMMON SHARE

Basic loss per share is based on the weighted-average number of common shares outstanding during each period. Diluted loss per share is based on basic shares as determined above, plus the incremental shares that would be issued upon the assumed exercise of “in-the- money” stock options and warrants using the treasury stock method and the inclusion of all convertible securities, including preferred stock and convertible notes, assuming these securities were converted at the beginning of the period or at the time of issuance, if later. The computation of diluted net loss per share does not assume the issuance of common shares that have an anti-dilutive effect on net loss per share.

For the three months and six months ended June 30, 2019 and 2018, the following options, warrants and convertible loans were excluded from the computation of diluted loss per share as the result of the computation was anti-dilutive:

	Three months ended June 30, 2019		Three months ended June 30, 2018		Six months ended June 30, 2019		Six months ended June 30, 2018

Stock options		2,916,910		1,382,945		2,916,910		1,382,945
Warrants		4,703,323		3,704,775		4,703,323		3,704,775
Convertible securities		799,989		3,457,134		799,989		3,457,134
		8,420,222		8,544,854		8,420,222		8,544,854

ICAGEN, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

22.

RELATED PARTIES

Richard Cunningham

On April 30, 2019, the Company issued ten year options exercisable over 154,616 shares of common stock at an exercise price of $3.50 per share, with immediate vesting.

Douglas Krafte

On April 30, 2019, the Company issued ten year options exercisable over 75,267 shares of common stock at an exercise price of $3.50 per share, with immediate vesting.

23.

COMMITMENTS AND CONTINGENCIES

As a result of the agreements that the Company entered into with Pfizer Research (NC), the Company is obligated to; (i) make additional payments in terms of the Asset Purchase and Collaboration Agreement that it entered into on June 26, 2015 with Pfizer including beginning in 2017, a quarterly earn out payment (the “Earn Out Payment”) of 10% of revenue earned during the quarter, with a minimum payment of $250,000 per quarter, up to a maximum aggregate payment of $10,000,000, such minimum being reduced to $50,000 for the quarters ending March 2017 to December 2018 and the difference between $250,000 or the quarterly amount paid and the actual calculation of deferred purchase consideration at 10% of gross revenue per quarter is being deferred and paid as one lump sum with the payment being made the quarter ended March 31, 2019, bearing interest at 12.5% per annum, which interest is payable quarterly. The earn out payments are currently being renegotiated with Pfizer Research (NC).

On June 19, 2017, the Company entered into a four-year employment agreement with Douglas Krafte, Ph.D., pursuant to which Dr. Krafte is entitled to an annual base salary of $285,000 and will be eligible for annual discretionary performance bonus payments of up to 35% of his base salary payable in cash, which bonus, if any, will be awarded in the sole and absolute discretion of the Company’s board of directors and the compensation committee of the board of directors. Dr. Krafte continues to be engaged as the Company’s Chief Scientific Officer. On November 20, 2018, the Company approved an amendment to the Company’s employment agreement with Dr. Krafte, increasing his annual salary to Two Hundred Ninety Five Thousand Dollars ($295,000) and increasing his target bonus to up to 50% of his base salary.

On November 20, 2018, the Company approved an amendment to the Company’s employment agreement with Mr. Cunningham, increasing his annual salary to Three Hundred Seventy Five Thousand Dollars ($375,000). Mr. Cunningham continues to be the Company’s Chief Executive Officer.

On August 31, 2018, the Company, and its wholly owned subsidiary, Icagen-T, entered into a Credit Agreement with an institutional investor (the “Purchaser”), pursuant to which the Purchaser advanced to the Company and Icagen-T, Inc., the aggregate principal sum of $15,250,000 pursuant to four year senior secured term loans, maturing on August 31, 2022, bearing interest at the rate of one month Libor plus 9.75%, with a minimum rate of 12% per annum (the “Term Loans”). The Term Loans amortize commencing on the last day of each month after August 31, 2020 at an amount equal to $152,500 (1.0% of the aggregate principal amount of $15,250,000).

24.

SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date of the unaudited condensed consolidated financial statements were available to be issued and has concluded that no such events or transactions took place that would require disclosure herein.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis is intended as a review of significant factors affecting our financial condition and results of operations for the periods indicated. The discussion should be read in conjunction with our consolidated financial statements and the notes presented herein and the consolidated financial statements and the other information set forth in our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on April 12, 2019. In addition to historical information, the following Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties. Our actual results could differ significantly from those anticipated in these forward-looking statements as a result of certain factors discussed herein and any other periodic reports filed and to be filed with the Securities and Exchange Commission.

Overview and financial condition

Icagen is a drug discovery company with a focus in Neuroscience and Rare Disease. The Icagen platform is unique as it integrates our current state of the art drug discovery engine along with an artificial intelligence (AI) computational platform that enables an accelerated path to drug discovery.

Our business model is focused on research collaborations and partnerships with large pharmaceutical and biotechnology companies and foundations who we partner with to support the discovery and development of innovative pharmaceuticals. These revenue-generating partnerships provide current funding while our co-owned pipeline of drug candidates provides the potential of additional significant long-term upside through milestone and royalty payments in new partnerships. The development and commercialization expense of these assets is being partially funded by our partners. In addition, the Company also retains a CRO-based fee-for-service revenue stream as a component of the business model.

For the past three years, a significant portion of our revenue has been derived from our operations as a partner research organization providing integrated drug discovery services with unique expertise in the field of ion channel, transporter, neuroscience and rare disease targets while also covering many other classes of drug discovery targets and therapeutic areas. Our customers are pharmaceutical and biotechnology companies to whom we offer our industry-leading scientific expertise and technologies to aid in their determination of which molecules to advance into late stage preclinical studies and ultimately clinical trials. The core of our offering is the discovery of pre-clinical drug candidates (PDC’s), which are lead molecules (Leads) that are selected to enter into in-vivo studies during the pre-clinical phase of drug discovery. We offer a full complement of pre-clinical drug discovery services which include; assay development technologies (including high throughput fluorescence, manual and automated electrophysiology and radiotracer flux assays), cell line generation, high-throughput and ultra-high-throughput screening, medicinal chemistry, computational chemistry and custom assay services to our customers. Our capabilities also include molecular biology and the use of complex functional assays, electrophysiology, bioanalytics and pharmacology. We believe that this integrated set of capabilities enhances our ability to help our customers identify drug candidates.

More recently, we have begun to focus on partnership and collaboration opportunities with third parties, and we have entered into two such collaborations that provide us with an opportunity to derive revenue not only from our standard fees for integrated early discovery services but also from future milestone and royalty revenue from product candidates that may be developed and commercialized with our aid. We have developed an in-house portfolio of assets targeting different indications that we believe would be ideal candidates for partnership opportunities.

Since inception, we have financed our operations primarily through private sales of our securities, settlement of legal matters and revenue we generate from the services we provide and upfront payments received from collaborations. We expect to continue to seek to obtain our required capital through the private sale of securities and revenue derived from the services we provide.

Subsequent to our acquisition of certain assets from Pfizer and Sanofi, a substantial portion of our revenue has been derived from our operations as a partner research organization from two commercial customers. We have also entered into Master Services Agreements (“MSA”) with other various pharmaceutical companies where we have agreed to perform certain services for them.

For the three and six months ended June 30, 2019 95.1% and 97.4% of our revenue was derived from commercial revenue. For the year ended December 31, 2018, 100% of our revenue was derived from commercial revenues. For the year ended December 31, 2017, 56.2% of our revenue was derived from commercial revenues, 42.4% was derived from deferred subsidy revenue and 1.4% was generated from Government revenue. Despite generating funds from commercial customers and collaborations/partnerships, we continue to experience losses and during 2018 raised money from the issuance of our Series C Preferred Stock, our Term Loans and our Subordinated Notes in order to fund our operations. We believe that our existing cash and cash equivalents, including the $5,000,000 up front fee that we received from Roche and the $2,800,000 that we raised from our sale of shares of Series C Preferred Stock, the $500,000 that we raised from the sale of our Subordinated Notes and the $15,250,000 that we raised from the sale of the Term Loans, of which $10,200,000 was used to repay our convertible debt, will not be sufficient to meet our anticipated cash needs for the next twelve months. We will need to generate additional revenue from operations and/or obtain additional financing to pursue our business strategy, to respond to new competitive pressures or to take advantage of opportunities that may arise. These factors raise substantial doubt of our ability to continue as a going concern. As a result, our independent registered public accounting firm included an explanatory paragraph in its report on our consolidated financial statements as of and for the year ended December 31, 2018 with respect to this uncertainty. To meet our financing needs, we are considering multiple alternatives, including, but not limited to, additional equity financings, debt financings and/or funding from partnerships or collaborations. There can be no assurance that we will be able to complete any such transactions on acceptable terms or otherwise.

Prior to our acquisition of the Icagen assets, substantially all of our revenue was derived from government grants related to the use of our XRpro technology. To date, we had been granted twenty-two grants and contracts from United States governmental agencies; of which nine were granted from the Department of Defense and thirteen were granted from the National Institutes of Health. We currently have one grant still active with the NIH.

As a result of the agreements that we entered into with Pfizer Research (NC) we have incurred significant obligations including the obligation: (i) make additional payments in terms of the Asset Purchase and Collaboration Agreement that we entered into on June 26, 2015 with Pfizer including beginning in 2017, a quarterly earn out payment (the “Earn Out Payment”) of 10% of revenue earned during the quarter, with a minimum payment of $250,000 per quarter, up to a maximum aggregate payment of $10,000,000, such minimum being reduced to $50,000 for the quarters ending March 2017 to December 2018 and the difference between $250,000 or the quarterly amount paid and the actual calculation of deferred purchase consideration at 10% of gross revenue per quarter is being deferred and paid as one lump sum with the payment being made for the quarter ended June 30, 2019, bearing interest at 12.5% per annum, which interest is payable quarterly. We are currently renegotiating the earn out payments with Pfizer Research NC.

Discussions with respect to our operations included herein include the operations of our operating subsidiaries, Icagen Corp and Icagen-T, Inc. We have another two subsidiary companies, Caldera Discovery Inc. and XRpro Sciences Inc., which have always been dormant.

Results of Operations for the three months ended June 30, 2019 and the three months ended June 30, 2018

Revenues

Revenues were $3,905,527 and $4,375,969 for the three months ended June 30, 2019 and 2018, respectively, representing a decrease of $470,442 or 11.0%. The decrease in revenue over the prior year is due to the recognition of the upfront payment and the FTE fees generated during the three months ended June 30, 2018 from the collaboration agreement entered into with the CFF in the prior year and a decline in revenue from Sanofi in terms of our agreement with them, offset by an increase in up-front revenue recognized and an increase in FTE based revenue from the Roche collaboration agreement. We have also seen a decline in certain ad-hoc revenue as we shift our business towards more collaborative long-term revenue relationships. Government revenue was $189,575 and $0 (representing 4.9% and 0% of total sales) for the three months ended June 30, 2019 and 2018, respectively.

We continue to market our services to several pharmaceutical and biotechnology companies with a bias towards collaborative drug discovery arrangements. We believe that we have a comprehensive product offering and substantial credibility to offer a full range of products including the advantages and value propositions of the XRpro® technology. While we are optimistic about our prospects, there can be no assurance about whether or when our products will generate sufficient revenues with adequate margins in order for us to be profitable.

Cost of goods sold

Cost of goods sold was $2,926,359 and $2,871,930 for the three months ended June 30, 2019 and 2018, respectively, an increase of $54,429 or 1.9%. Cost of goods sold is primarily comprised of direct expenses related to providing our services to our customers. These direct expenses include salary expenses directly related to our statements of work and research contracts including those of our scientific personnel, recoverable expenses incurred on contracts, the cost of outside consultants, and direct materials used on our contracts.

●

The salary expense included in cost of goods sold for the three months ended June 30, 2019 and 2018, respectively was $1,627,726 and $1,679,562, a decrease of $51,836 or 3.1%. This is primarily due to a reduction in the number of personnel at our Tucson facility, a change in our bonus policy, and the number of personnel working on Sanofi projects, partially offset by the number of personnel working on new business, including the Roche and Cystic Fibrosis collaboration agreements. For additional information regarding salary expense reference is made to the discussion of total salary expense in Selling, general and administrative expenses below.

●

The laboratory supplies and direct materials included in cost of goods sold for the three months ended June 30, 2019 and 2018, respectively was $992,154 and $980,262, an increase of $11,892 or 1.2%, the increase is immaterial.

●

Outside contractors’ cost included in cost of goods sold for the three months ended June 30, 2019 and 2018, respectively, amounted to $230,033 and $212,106 an increase of $17,927 or 8.5% which is due to third party maintenance expenditure which is amortized over the period of the maintenance contract. New contracts were entered into for both the North Carolina and Tucson facilities during the current period.

Gross profit

Gross profit was $979,168 and $1,504,039 for the three months ended June 30, 2019 and 2018, respectively, an increase of $524,871 or 34.9%. The decrease in gross profit is primarily due to the decreased revenue, discussed above.

Selling, general and administrative expenses

Selling, general and administrative expenses was $3,105,311 and $2,648,322 for the three months ended June 30, 2019 and 2018, respectively, an increase of $456,989 or 17.3%.

The major expenses making up selling, general and administrative expenses included the following:

	Three months ended June 30,				Increase/			Percentage
	2019		2018		(decrease)			change

Marketing and selling expenses	$	7,811	$	11,289	$	(3,478	)		(30.8	)%
Payroll expense		393,346		607,418		(214,072	)		(35.2	)%
Research and development salaries		506,664		676,583		(169,919	)		(25.1	)%
Directors fees		55,000		55,000		-			-	%
Stock option compensation charge		938,166		151,713		786,453			518.4	%
Legal fees		119,428		113,002		6,426			5.7	%
Consulting fees		156,900		127,838		29,062			22.7	%
Facilities expense		587,870		665,869		(77,999	)		(11.7	)%
Travel expenditure		88,426		23,993		64,433			268.5	%
Other expenses		251,700		215,617		36,083			16.7	%
	$	3,105,311	$	2,648,322	$	456,989			17.3	%

The decrease in marketing expenditure over the prior period is primarily due a change in strategy with less reliance placed on developing a comprehensive Contract Research Organization (“CRO”) business model and focusing on collaborative agreements with specific customers, therefore less marketing effort was required during the current period.

Total salary expenses are allocated to the various expense categories detailed below depending on the level of activity of our employees on our commercial projects, internal research and development expenses and administrative activities. An increase in activity on projects will result in an increase in salary expense charged to cost of goods sold with a corresponding decrease in salary expense charged to research and development. A comparison of salary expenses is presented below.

Total salary expenditure for the three months ended June 30, 2019 and 2018, respectively is included in the following expense categories:

	Three months ended June 30,				Increase/			Percentage
	2019		2018		(decrease)			change

Cost of sales	$	1,627,726	$	1,679,562	$	(51,836	)		(3.1	)%
Selling, general and administrative expenses		393,346		607,418		(214,072	)		(35.2	)%
Research and development salaries		506,664		676,583		(169,919	)		(25.1	)%
	$	2,527,736	$	2,963,563	$	(435,827	)		(14.7	)%

The decrease in total salary expenditure of $435,827 or 14.7% is primarily due to the restructure of our management team and the streamlining of operations at our Tucson site. We also changed our policy of accruing for bonuses which is now milestone based and will only be accrued on the achievement of specific milestones.

The payroll expense charged to cost of goods sold decreased by $51,836 or 3.1% due to the reasons discussed under cost of goods sold above and the elimination of the bonus accrual in the current period.

The payroll expense charged to Selling, general and administrative expenses decreased by $214,072 or 35.2%, primarily due to the restructure of our Tucson management team and the streamlining of our operations, together with a reduction in the overall bonus accrual for management.

The research and development salaries decreased by $169,919 or 25.1% primarily due to the streamlining of operations at our Tucson facility by the reduction in scientific staff.

Directors’ cash fees remained the same as the prior year, with no increase in directors’ headcount and with approved fees retained at prior year levels.

The stock option compensation charge increased by $786,453 or 518.4%. The charge for each period is dependent upon the number of options granted, any new options issued, the value of the options and the vesting schedule of these options. During April 2019, 628,883 options to purchase shares of common stock were issued to our directors, executive officers and consultants. These options resulted in an increased expense in the current period as approximately 230,000 of these options vested immediately with the balance vesting over a period of thirty six months.

Legal fees increased by $6,426 or 5.7%. The increase is primarily due to an increase in our general corporate legal fees.

The increase in consulting fees of $29,062 or 22.7% is primarily due to the increase in technical consulting and management fees by consultants considered to be experts in their fields.

Facilities expense decreased by $77,999 or 11.7%, primarily due to a decrease in outside services such as cleaning and janitorial, and security services.

Travel expenditure increased by $64,433 or 268.5%, primarily due to additional travel incurred by our CSO and CEO in managing the Tucson facility as well as additional travel for our scientific personnel associated with our collaboration agreements.

Other expenses represent various insignificant individually insignificant expenses.

Depreciation and Amortization

Depreciation expense was $366,876 and $368,274 for the three months ended June 30, 2019 and 2018, respectively, a decrease of $1,398 or 0.4%. The depreciation expense is primarily made up of depreciation of our laboratory equipment and software licensing, which makes up the majority of our capital assets.

Amortization expense was $56,246 for the three months ended June 30, 2019 and 2018.

Other income

Other income was $1,599 and $0 for the three months ended June 30, 2019 and 2018, respectively, an increase of $1,599 or 100.0%. Other income consisted of proceeds received from assets disposed of by an agent on our behalf.

Interest expense

Interest expense was $791,066 and $791,210 for the three months ended June 30, 2019 and 2018, respectively.

The interest expense consists of the following;

●

Imputed interest cost of $65,577 and $74,769 for the three months ended June 30, 2019 and 2018, respectively, a decrease of $9,192 or 12.3%, the imputed interest is based on the length of time to repay the Pfizer deferred purchase consideration based on our future revenue projections and minimum payments we are required to make;

●

The amortization of debt discount of $179,450 and $358,625 for the three months ended June 30, 2019 and 2018, respectively, a decrease of $179,175 or 50.0%, The decrease is primarily due to the amortization of discount associated with the GBP convertible debt which was repaid in August 2018;

●

interest expense of $545,797 and $357,816 for the three months ended June 30, 2019 and 2018, respectively, an increase of $187,981 or 52.5%, the increase is primarily due to the increase in borrowing from $10,000,000 in 2018 to $15,250,000 in 2019, the interest due on bridge notes still outstanding and the interest incurred on the Pfizer deferred purchase consideration;

●

Other interest was $242 and $0 for the six months ended June 30, 2019 and 2018, respectively.

Derivative liability movement

Derivative liability movement was a gain of $942,288 and a loss of $(1,140,623) for the three months ended June 30, 2019 and 2018, respectively, a net movement of $2,082,911. The credit during the current period represents the mark to market of the derivative liability calculated on the warrants issued with the prior period convertible debt and the Series C Preferred stock warrants, with variable pricing options and possible cash settlement upon the occurrence of a fundamental event.

Net loss

Net loss was $2,396,445 and $3,500,636 for the three months ended June 30, 2019 and 2018, respectively, a decrease of $1,104,191 or 31.5%. The decrease in net loss is attributable to the movement in the mark to market value of our derivative liability which increased by $2,082,911, as discussed above.

Preferred stock dividends

Preferred stock dividends was $83,770 and $59,540 for the three months ended June 30, 2019 and 2018, respectively. The Series C Preferred stock issued in the current period earns dividends at the rate of 12% per annum.

Net loss available to common stockholders

The net loss available to common stockholders was $2,480,215 and $3,560,176 for the three months ended June 30, 2019 and 2018, respectively, a decrease of $1,079,961 or 30.3%. This is due to the reasons discussed above.

Results of Operations for the six months ended June 30, 2019 and the six months ended June 30, 2018.

Sales

We had sales totaling $7,366,038 and $7,457,118 for the six months ended June 30, 2019 and 2018, respectively, a decrease of $91,080 or 1.2%. Sales includes services revenue of $7,176,463 (representing 97.4% of total sales) and $7,457,118 (representing 100% of total sales for the six months ended June 30, 2019 and 2018, respectively, a decrease of $280,655 or 3.8%. The decrease is primarily attributable to the recognition of $1,000,000 in CFF revenue in the prior period on closing the agreement with them, offset by the recognition of upfront revenue and FTE revenue derived from the collaboration agreement with Roche. Government revenue was $189,575 and $0 (representing 2.6% and 0% of total sales, respectively) for the six months ended June 30, 2019 and 2018, respectively.

We continue to market our services to several pharmaceutical and biotechnology companies. We believe that we now have a comprehensive product offering and substantial credibility to offer a full range of products including our proprietary XRPro® technology. While we are optimistic about our prospects, there can be no assurance about whether or when our products will generate sufficient revenues with adequate margins in order for us to be profitable.

Cost of sales

Cost of sales totaled $4,969,346 and $5,521,244 for the six months ended June 30, 2019 and 2018, respectively, a decrease of $551,898 or 10.0%. Cost of sales is primarily comprised of direct expenses related to providing our services to our customers. These direct expenses include salary expenses directly related to our statements of work and research contracts including those of our scientific personnel, recoverable expenses incurred on contracts, the cost of outside consultants, and direct materials used on our contracts.

●

The salary expense included in cost of sales for the six months ended June 30, 2019 and 2018 respectively was $2,795,300 and $3,302,752 a decrease of $507,452 or 15.4%. The decrease is primarily due to a reduction in overall personnel costs by reducing the bonus accrual on expected lower payments and the number of commercial contracts currently underway. For additional information regarding salary expense reference is made to the discussion of total salary expense in Selling, general and administrative expenses below.

●

The laboratory supplies and direct materials included in cost of sales for the six months ended June 30, 2019 and 2018, amounted to $1,702,747 and $1,795,110 a decrease of $92,363 or 5.1%, which decrease is primarily due to the reduction in usage of expensive consumables on current business, these consumables expenses are generally passed through to our customers at low margins.

●

Outside contractors’ cost included in cost of sales for six months ended June 30, 2019 and 2018, respectively, amounted to $471,299 and $423,382 an increase of $47,917 or 11.3% which is due primarily to repairs and maintenance expenditure for laboratory equipment.

Gross profit

Gross profit amounted to $2,396,692 and $1,935,874 for the six months ended June 30, 2019 and 2018, respectively, an increase of $460,818 or 23.8%, primarily due to the improvement in cost of sales discussed above.

Selling, general and administrative expenses

Selling, general and administrative expenses was $5,754,470 and $5,640,644 for the six months ended June 30, 2019 and 2018, respectively, an increase of $113,826 or 2.0%.

The major expenses making up selling, general and administrative expenses included the following:

	Six months ended June 30,				Increase/			Percentage
	2019		2018		(decrease)			change

Marketing and selling expenses	$	13,153	$	46,551	$	(33,398	)		(71.7	)%
Payroll expense		890,223		1,373,646		(483,423	)		(35.2	)%
Research and development salaries		1,324,876		1,535,778		(210,902	)		(13.7	)%
Directors fees		110,000		110,000		-			-	%
Stock option compensation charge		1,202,104		305,620		896,484			293.3	%
Legal fees		162,505		231,199		(68,694	)		(29.7	)%
Consulting fees		276,145		264,308		11,837			4.5	%
Facilities expense		1,143,480		1,266,988		(123,508	)		(9.7	)%
Travel expenditure		140,259		48,555		91,704			188.9	%
Other		491,725		457,999		33,726			7.4	%
	$	5,754,470	$	5,640,644	$	113,826			2.0	%

The decrease in marketing expenditure over the prior period is primarily due a change in strategy with less reliance placed on developing a comprehensive CRO business model, therefore less marketing effort was required during the current period.

Total payroll expenses are allocated to the various expense categories detailed below:

	Six months ended June 30,				Increase/			Percentage
	2019		2018		(decrease)			change

Cost of sales	$	2,795,300	$	3,302,752	$	(507,452	)		(15.4	)%
Selling, general and administrative expenses		890,223		1,373,646		(483,423	)		(35.2	)%
Research and development salaries		1,324,876		1,535,778		(210,902	)		(13.7	)%
	$	5,010,399	$	6,212,176	$	(1,201,777	)		(19.3	)%

The decrease in total payroll expenditure is primarily due to the restructure of our operations with the release of our business development team due the change in our market focus from CRO to early stage drug discovery and the reduction in bonus accrual due to anticipated lower payouts.

The total payroll expense included in cost of sales decreased by $507,452 primarily due to a reduction in the level of activity on current projects during the current period.

The payroll expense charged to selling, general and administrative expenses decreased by $483,423 is primarily due to the restructure of the organization and the release of the business development team and lower bonus and vacation accruals during the current period.

The payroll expense charged to research and development decreased by $210,902. The decrease is due to higher utilization of scientific personnel on internal projects during the current period and a reduction in overall headcount.

Directors’ fees remained the same as the prior period, there was no increase in fee or directors’ headcount.

The stock option compensation charge increased by $896,484. The charge for each period is dependent upon the number of options granted, any new options issued, the value of the options and the vesting schedule of these options. During April 2019, 628,883 options to purchase shares of common stock were issued to our directors, executive officers and consultants. These options resulted in an increased expense in the current period as approximately 230,000 of these options vested immediately with the balance vesting over a period of thirty six months.

Legal fees decreased by $68,694. The prior period included significant legal fees incurred in the GPB debt funding. The legal fees incurred in the current period consist of patent related activities and general legal counsel.

Consulting expenses increased by $11,837, which increase is due to technical advice received regarding the government grant awarded to us in May 2019.

Facilities expenses decreased by $123,508 primarily due to a decrease in outside services such as cleaning and janitorial, and security services.

Travel expenditure increased by $91,704 primarily due to additional travel incurred by our CSO and CEO in managing the Tucson facility as well as additional travel for our scientific personnel associated with our collaboration agreements.

Other expenses consist of various small expenses which are individually insignificant, the increase is primarily due to the administrative expenses related to the acquisition of the Tucson facility and the increase in the activity of the sales activity over the prior period.

Depreciation and Amortization

We recognized depreciation expenses of $827,541 and $825,730 for the six months ended June 30, 2019 and 2018 respectively, an increase of $1,811 or 0.2%. The depreciation expense is primarily made up of depreciation of our laboratory equipment and software licensing, which makes up the majority of our capital assets

Amortization expense was $112,492 and $112,492 for the six months ended June 30, 2019 and 2018, respectively.

Other income

Other income was $1,599 and $6,384 for the six months ended June 30, 2019 and 2018, respectively, a decrease of $4,785 or 75.0%. Other income consisted of proceeds received for assets sold by a third party.

Interest expense

Interest expense totaled $1,565,906 and $1,550,932 for the six months ended June 30, 2019 and 2018, respectively.

The interest expense consists of the following:

●

Imputed interest on deferred purchase consideration on the acquisition of the North Carolina facility of $131,154 and $149,538 for the six months ended June 30, 2019 and 2018, a decrease of $18,384 or 12.3%, respectively. the imputed interest is based on the length of time to repay the Pfizer deferred purchase consideration based on our future revenue projections and minimum payments we are required to make;

●

The amortization of debt discount of $355,719 and $694,010 for the six months ended June 30, 2019 and 2018, respectively, a decrease of $338,291 or 48.7%. The decrease is primarily due to the amortization of discount associated with the GBP convertible debt which was repaid in August 2018;

●

Interest expense was $1,078,791 and $706,845 for the six months ended June 30, 2019 and 2018, respectively, an increase of $371,946 or 52.6%, the increase is primarily due to the increase in borrowing from $10,000,000 in 2018 to $15,250,000 in 2019, the interest due on bridge notes still outstanding and the interest incurred on the Pfizer deferred purchase consideration

●

Other interest was $242 and $539 for the six months ended June 30, 2019 and 2018, respectively.

Derivative liability movement

Derivative liability movement was $712,020 and $(1,045,537) for the six months ended June 30, 2019 and 2018, respectively, a net movement of $1,757,557. The credit during the current period represents the mark to market of the derivative liability raised on the warrants issued and the beneficial conversion feature of the Convertible Debt and the Series C Preferred stock warrants, with variable pricing options.

Net loss

Net loss was $5,150,098 and $7,233,077 for the six months ended June 30, 2019 and 2018, respectively, a decrease of $2,082,979 or 28.8%. The reduction in the net loss is attributable to the increase in upfront and FTE based revenue related to the Roche collaboration agreements and an increase in mark-to-market derivative liabilities.

Preferred stock dividends

Preferred stock dividends was $166,619 and $59,540 for the six months ended June 30, 2019 and 2018, respectively. The Series C Preferred stock issued in the current period earns dividends at the rate of 12% per annum.

Net loss available to common stockholders

The net loss available to common stockholders was $5,316,717 and $7,292,617 for the six months ended June 30, 2019 and 2018, respectively, a decrease of $1,975,900 or 27.1%. This is due to the reasons discussed above.

Liquidity and Capital Resources

We have a history of operating losses and net losses since inception and we have primarily funded our operations through sales of our unregistered equity securities and cash flows generated from government contracts and grants, settlement of lawsuits and more recently from debt funding, commercial customers and subsidy income. Although, we are generating revenue from commercial customers, we continue to experience losses and will need to raise additional funds in the future to meet our working capital requirements. To date, we have never generated sufficient cash from operations to pay our operating expenses. We have received $29,000,000 from Sanofi and despite the $3,000,000 we expect to derive from Icagen-T for services provided to Sanofi over the next twelve months, we expect our expenses to increase as our operations expand and our expenses may continue to exceed such revenue. During the year ended December 31, 2018, we raised an additional $2,800,000 through the issuance of shares of our Series C Preferred stock, an additional $500,000 through the issuance of Bridge Notes and a further $15,250,000 in Term Loans of which $10,200,000 was utilized to settle convertible debt outstanding. As of June 30, 2019, despite our fund raising efforts mentioned in the preceding sentence, we had not generated sufficient additional revenue from operations to pursue our business strategy, to respond to new competitive pressures or to take advantage of opportunities that may arise. These factors raised substantial doubt about our ability to continue as a going concern. As a result, our independent registered public accounting firm included an explanatory paragraph in its report on our consolidated financial statements as of and for the year ended December 31, 2018 with respect to this uncertainty. We anticipate that our current cash and cash equivalents, including cash derived from the Series C Preferred Stock issued, the term loans and the bridge notes will not be sufficient to meet our operating needs during the quarter ending September 30, 2019 without additional revenue derived from operations, collaborations or financings. If we should require additional capital, we may consider multiple alternatives, including, but not limited to, additional equity financings, debt financings and/or funding from partnerships or collaborations. There can be no assurance that we will be able to complete any such transactions on acceptable terms or otherwise.

As of June 30, 2019, we had cash totaling $929,953, other current assets totaling $1,685,604 and total assets of $12,455,702. We had total current liabilities of $12,042,293 and a net working capital deficit of $9,426,736. Total liabilities were $35,928,023 including net deferred purchase consideration of $8,612,893. The deferred purchase consideration includes a net present value discount of $987,107 (made up of a gross present value discount of $2,468,700 less imputed interest movements of $1,481,593), the gross amount still due in terms of the acquisition agreement with Pfizer, Inc., is $9,600,000 after the payment of $400,000 to date, based on a potential earn out charge of the greater of (i) 10% of gross revenues commencing in January 2017 per quarter and (ii) $250,000 per quarter, up to a maximum of $10,000,000 of which amounts in excess of $50,000 can be deferred and $200,000 was deferred for the quarters ended March 31, 2017 through to, December 31, 2018. The deferred amount bears interest at a rate of 12.5% per annum. Our stockholders’ deficit amounted to $23,472,322.

Should we not achieve our forecasted operating results, or should strategic opportunities present themselves such that additional financial resources would present attractive investing opportunities for us, we may decide in the future to issue debt or sell our equity securities in order to raise additional cash. We cannot provide any assurances as to whether we will be able to secure any additional financing, or the terms of any such financing transaction if one were to occur.

Cash Flows

An analysis of our cash flows from operating, investing and financing activities for the six months ended June 30, 2019 and 2018 is provided below.

	Six months ended June 30,						Increase/			Percentage
	2019			2018			(decrease)			change

Net cash used in operating activities	$	(2,822,110	)	$	(2,578,428	)	$	(243,682	)		9.5	%
Net cash used in investing activities		(1,002,810	)		(507,727	)		(495,083	)		97.5	%
Net cash provided by financing activities		635,815			1,988,888			(1,353,073	)		(68.0	)%
Net (decrease) increase in cash and cash equivalents	$	(3,189,105	)	$	(1,097,267	)	$	(2,091,838	)		190.6	%

Net cash used in operating activities was $(2,822,110) and $(2,578,428) for the six months ended June 30, 2019 and 2018, respectively. The increase in cash used in operating activities was primarily due to the following:

	Six months ended June 30,						Increase/			Percentage
	2019			2018			(decrease)			change

Net loss	$	(5,150,098	)	$	(7,233,077	)	$	2,082,979			(28.8	)%
Adjustments for non-cash items		1,916,989			3,132,927			(1,215,938	)		(38.8	)%
Changes in operating assets and liabilities		410,999			1,521,722			(1,110,723	)		(73.0	)%
Net cash used in operating activities	$	(2,822,110	)	$	(2,578,428	)	$	(243,682	)		9.5	%

The decrease in net loss is discussed under net loss in the results of operations for the six months ended June 30, 2019 and 2018, respectively.

The change in adjustments for non-cash items of $(1,215,938) is primarily due to; i) an increase in the movement of derivative liabilities of $(1,757,557); a decrease in the amortization of debt discount of $(338,291); offset by ii) the increase in the movement of stock based compensation of $896,484 primarily due to the number of options issued during April 2019 which are being amortized in the current period.

The decrease in the movement in operating assets and liabilities of $(1,110,723) included (i) a decrease in the movement in accounts payable balances of $(913,334); (ii) a decrease in the movement of deferred revenues of $(583,334) due to the recognition of revenue from upfront payments; offset by (iii) the increase in the movement of receivables balances of $761,558, primarily due to certain collaboration customers providing us with upfront payments on FTE and Consumable expenditure to be incurred;

Net cash used in investing activities increased by $495,083 primarily due to the acquisition of new laboratory equipment during the current period to increase our efficiencies and the payment of deferred purchase consideration of $100,000 during the current period.

Net cash provided by financing activities decreased by $1,353,073, primarily due to; i) the funding of the laboratory equipment mentioned above of $655,133, a reduction in the movement of repayment of finance leases of $86,475 and the proceeds received on Series C preferred stock of $2,100,000 in the prior period.

Capital Expenditures

Our current plan is to purchase equipment and software to ensure that the Tucson Facility and the Icagen NC Facility function efficiently and that we are able to support the commercialization efforts of the Company. We anticipate that we would need to spend an additional $1,200,000 on necessary software and approximately $300,000 on equipment over the next twelve months.

Other Commitments

As a result of the agreements that we entered into with Pfizer we are obligated; (i) make additional payments in terms of the Asset Purchase and Collaboration Agreement that we entered into on June 26, 2015 with Pfizer including beginning in 2017, a quarterly earn out payment (the “Earn Out Payment”) of 10% of revenue earned during the quarter, with a minimum payment of $250,000 per quarter, up to a maximum aggregate payment of $10,000,000, such minimum being reduced to $50,000 for the quarters ending March 2017 to December 2018 and the difference between $250,000 or the quarterly amount paid and the actual calculation of deferred purchase consideration at 10% of gross revenue per quarter is being deferred and paid as one lump sum with the payment being made the quarter ended June 30, 2019, bearing interest at 12.5% per annum, which interest is payable quarterly.

We have recently entered into a thirty six month operating lease agreement for approximately 11,207 square feet located at Suite 350 and suite 380, 4222 Emperor Boulevard, Durham, North Carolina. The undiscounted future minimum lease payments in terms of the lease amount to $688,221. The Company paid a deposit of $19,612 on commencement of the lease.

The amount of future minimum lease payments under finance leases as of June 30, 2019 are as follows:

	Amount

Remainder of 2019	$	117,674
2020		240,054
2021		247,264
2022		83,229
Total undiscounted minimum future lease payments	$	688,221

Recently Issued Accounting Pronouncements

The recent Accounting Pronouncements are fully disclosed in note 2 to our unaudited condensed consolidated financial statements.

Management does not believe that any other recently issued but not yet effective accounting pronouncements, if adopted, would have an effect on the accompanying unaudited condensed consolidated financial statements.

Off-balance sheet arrangements

We do not maintain off-balance sheet arrangements, nor do we participate in non-exchange traded contracts requiring fair value accounting treatment.

Inflation

The effect of inflation on our revenue and operating results was not significant.

Climate Change

We believe that neither climate change, nor governmental regulations related to climate change, have had, or are expected to have, any material effect on our operations.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Not applicable.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

The Company has adopted and maintains disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in the reports filed under the Exchange Act, such as this Quarterly Report on Form 10-Q, is collected, recorded, processed, summarized and reported within the time periods specified in the rules of the Securities and Exchange Commission. The Company’s disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to management to allow timely decisions regarding required disclosure. As required under Exchange Act Rule 13a-15, the Company’s management, including the Principal Executive Officer and the Principal Financial Officer, has conducted an evaluation of the effectiveness of disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, the Company’s CEO and CFO concluded that due to a lack of segregation of duties the Company’s disclosure controls and procedures are not effective to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including the Company’s CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Subject to receipt of additional financing or revenue generated from operations, the Company intends to retain additional individuals to remedy the ineffective controls.

Changes in Internal Control

There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during our fiscal quarter ended June 30, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 1A. Risk Factors.

The following information updates, and should be read in conjunction with, the information disclosed in Part 1, Item IA, “Risk Factors,” contained in our Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the SEC on April 12, 2019. Except as disclosed below, there have been no material changes from the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018.

Risk related to the Company

We have a history of losses and there can be no assurance that we will generate or sustain positive earnings.

For the six months ended June 30, 2019 we had a net loss of $5,150,098 and for the year ended December 31, 2018 we had a net loss of $13,039,313. The only year that we had net income was the year ended December 31, 2014 when we received proceeds from the settlement of the Los Alamos National Security, LLC matter. We cannot be certain that our business strategy will ever be successful. Future revenues and profits, if any, will depend upon various factors, including the success, if any, of our expansion plans and our services to biotechnical and pharmaceutical customers, successful development and commercialization of product candidates, marketability of our technology, instruments and services, our ability to maintain favorable relations with manufacturers and customers, and general economic conditions. There is no assurance that we can operate profitably or that we will successfully implement our plans. There can be no assurance that we will ever generate positive earnings.

A significant portion of our net revenue has been generated from services provided to a limited number of our customers.

For the six months ended June 30, 2019 we derived 97.4% of our revenues from commercial sales and 81.7% of our commercial revenues was derived from four customers during the six months ended June 30, 2018. For the year ended December 31, 2018, we derived 100% of our revenues from commercial revenues for services provided to pharmaceutical and biotech customers, of which 89.3% and 83.4%, respectively was derived from seven customers. Our business model which now concentrates on commercial customers is relatively new and there can be no assurance that we will be able to increase the revenue derived from commercial customers to a significant amount. Our master services agreement with Sanofi guaranteed $32 million over a five-year period of which $29,000,000has been received and a further $3,000,000 is expected to be paid in the next 15 months, subject to us meeting certain terms and conditions. There can be no assurance that we will attract a sufficient number of other pharmaceutical companies to provide our services to or that Pfizer, Sanofi and our other customers will continue to use our services or that Sanofi will increase the scope of the services required. We do not have enough information regarding our new business model to assess its success.

We will need to generate significant revenue or raise additional capital to fully implement our business plan and meet our existing obligations, which may not be available on commercially reasonable terms, or at all, and which may dilute your investment.

We incurred a net loss of $5,150,098 for the six months ended June 30, 2019 and a net loss of $13,039,313 for the year ended December 31, 2018. Achieving and sustaining profitability will require us to increase our revenues and manage our product, operating and administrative expenses. We cannot guarantee that we will be successful in achieving profitability. Pursuant to the terms of our asset purchase agreement with Pfizer, as amended July 15, 2016 (the Pfizer APA), we are required to pay Pfizer, a lump sum of unpaid deferred purchase consideration due for the period January 1, 2017 to December 31, 2018 of $1,600,000, the deferred portion of the quarterly payments from January 2017 until December 31, 2018 on March 31, 2019 and thereafter a minimum payment of $250,000 each quarter up to a maximum of $10,000,000. Pursuant to the terms of our asset purchase agreement with Sanofi (the Sanofi APA), our subsidiary, Icagen-T, agreed to maintain and pay the maintenance costs of the Sanofi chemical libraries that remain at the Tucson Facility. We are also required to make significant payments under the terms of our outstanding term loans. If we are unable to generate sufficient revenues to pay our expenses and our existing sources of cash and cash flows are otherwise insufficient to fund our activities, we will need to raise additional funds to continue our operations at their current level and in order to fully implement our business plan. We do not have any commitments in place for additional funds. If needed, additional funds may not be available on favorable terms, or at all. As of the date hereof, we expect that our current cash and revenues generated from services, our private placement financings will provide us with enough funds to continue our operations at our current level for the next six months. Unless we raise additional funds or increase revenues, we will be forced to curtail our operations and limit our marketing expenditures. Furthermore, if we issue equity or debt securities to raise additional funds, our existing stockholders may experience dilution, and the new equity or debt securities, such as senior secured notes, may have rights, preferences and privileges senior to those of our existing stockholders. If we are unsuccessful in achieving profitability and we cannot obtain additional funds on commercially reasonable terms or at all, we may be required to curtail significantly or cease our operations significantly, it could result in the loss of all of your investment in our stock.

RISKS RELATED TO OUR DEBT OBLIGATIONS

Our substantial leverage may impair our financial condition and prevent us from fulfilling our obligations under the notes.

We have a substantial amount of indebtedness. As of June 30, 2019, principal debt owed under the Term Loans and 10% Subordinated Promissory Notes was $15.25 million (disclosed as $13.03 million net of debt discount of $2.2 million). Our substantial leverage could have important consequences to investors, including:

●

making it more difficult for us to satisfy our obligations with respect to the Term Loans and other debt;

●

increasing our vulnerability to general adverse economic and industry conditions by making it more difficult for us to react quickly to changing conditions;

●

limiting our ability to obtain additional financing to fund future working capital, capital expenditures, acquisitions and other general corporate requirements;

●

requiring a substantial portion of our cash flow from operations for the payment of interest on our indebtedness and reducing our ability to use our cash flow to fund working capital, capital expenditures, acquisitions and general corporate requirements;

●

limiting our flexibility in planning for, or reacting to, changes in our business, and the industry in which we operate; and

●

placing us at a competitive disadvantage compared with our competitors that have less indebtedness.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None that have not been previously reported.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6.Exhibits

10.1	Lease by and between Icagen, Inc. and Durham Royal Center, LLC, dated as of April 30, 2019 (Incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on May 2, 2019 (File No. 000-54748)
31.1	Certification of Richard Cunningham, Chief Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a) (1)
31.2	Certification of Mark Korb, Chief Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a) (1)
32.1	Certification of Richard Cunningham, Chief Executive Officer, pursuant to Section 1350 of the Sarbanes-Oxley Act of 2002 (1)
32.2	Certification Mark Korb, Chief Financial Officer pursuant to Section 1350 of the Sarbanes-Oxley Act of 2002 (1)
101.	INS XBRL Instance Document (1)
101.	SCH XBRL Taxonomy Extension Schema Document (1)
101.	CAL XBRL Taxonomy Extension Calculation Linkbase Document (1)
101.	DEF XBRL Taxonomy Extension Definition Linkbase Document (1)
101.	LAB XBRL Taxonomy Extension Label Linkbase Document (1)
101.	PRE XBRL Taxonomy Extension Presentation Linkbase Document (1)

(1)

Filed herewith

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned.

ICAGEN, INC.

/s/ Richard Cunningham
Richard Cunningham
Chief Executive Officer and President
(Principal Executive Officer)

/s/ Mark Korb
Mark Korb
Chief Financial Officer
(Principal Financial and Accounting Officer)

Date: August 19, 2019

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. senior Avg

Icagen 10-Q2019 Q2 Quarterly report

Content analysis